[{"text": "LIVE The latest news and updates on Trump's tariffs Is Aldeyra Therapeutics (ALDX) Among Billionaire Joseph Edelman\u2019s Long-Term Stock Picks? Usman Kabir Mon, Jan 20, 2025, 11:28 PM 4 min read In This Article: ALDX -1.34% We recently published a list of Billionaire Joseph Edelman's Top 10 Long-Term Stock Picks . In this article, we are going to take a look at where Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) stands against other Billionaire Joseph Edelman\u2019s long-term stock picks. Joseph Edelman is a renowned figure in the investment world, recognized for his expertise in biotechnology and healthcare investing. As the founder, CEO, and portfolio manager of Perceptive Advisors , Edelman has built a reputation as one of the most successful and insightful investors in the biotech sector. His deep understanding of the scientific, clinical, and financial aspects of the industry has enabled him to identify promising companies and generate significant returns for his investors. Joseph Edelman earned his Bachelor of Arts in Psychology from the University of California, San Diego, and later pursued an MBA from NYU Stern School of Business. He began his career as a biotechnology analyst at Prudential Securities and subsequently worked as a portfolio manager at Paramount Capital Asset Management. These early roles provided Edelman with a foundation in analyzing biotech companies, understanding their value drivers, and assessing the risks associated with drug development and regulatory approval processes. Read more about these developments by accessing 10 Best AI Data Center Stocks and 10 Buzzing AI Stocks According to Goldman Sachs . In 1999, Edelman founded Perceptive Advisors, a New York-based investment firm focused on the life sciences sector. The firm initially launched with a single hedge fund, the Perceptive Life Sciences Fund, and has since expanded to manage billions of dollars in assets. Perceptive Advisors specializes in identifying high-growth potential in emerging biotech, pharmaceutical, and healthcare companies, with an emphasis on innovation in areas such as gene therapy, oncology, and rare diseases. Under Edelman\u2019s leadership, Perceptive Advisors has achieved remarkable success. The firm manages over $4.7 billion in the 13F portfolio as of the end of the third quarter of 2024. The Perceptive Life Sciences Fund has delivered annualized returns exceeding 15% over the past two decades, far outpacing broader market indices. Edelman has been an early backer of biotech companies that went on to achieve significant breakthroughs, including Moderna and CRISPR Therapeutics. While Edelman\u2019s track record is stellar, the biotech sector\u2019s inherent risks mean that not all investments succeed. Regulatory setbacks, clinical trial failures, and market sentiment can lead to significant volatility. Story Continues Read more about these developments by accessing 30 Most Important AI Stocks According to BlackRock and Beyond the Tech Giants: 35 Non-Tech AI Opportunities . For this article, we selected stocks by combing through the 13F portfolio of Perceptive Advisors at the end of the third quarter of 2024. Only the companies that have been in the 13F portfolio of the fund consistently for the past three years were selected. These stocks are also popular among other hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter\u2019s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points ( see more details here ). Is Aldeyra Therapeutics, Inc. (ALDX) Among Billionaire Joseph Edelman\u2019s Long-Term Stock Picks? A medical researcher in a laboratory focusing on a diagnosis of an ocular disease. Aldeyra Therapeutics, Inc. (NASDAQ: ALDX ) Number of Hedge Fund Holders: 11 Perceptive Advisors\u2019 Stake: $6.1 million Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) is a biotechnology company devoted to improving lives by inventing, developing, and commercializing next-generation medicines that treat immune-mediated, autoimmune and metabolic diseases. The following factors make Aldeyra Therapeutics (NASDAQ:ALDX) a great investment opportunity. First, significant financial growth was seen, as illustrated in the report of the third quarter of 2024, highlighting $122.9 million in cash and cash equivalents. Secondly, innovative projects, like introducing Reproxalap, a new drug application for the treatment of dry eye disease, serve as a great milestone for the company. As per the recent news, the New Drug Application (NDA) for Reproxalap has been accepted for review by the US Food and Drug Administration (FDA), with a Prescription Drug User Fee Act (PDUFA) date set for April 2025. Moreover, the company has expanded its pipeline into retinal diseases through the acquisition of Helio Vision, a company focused on developing therapies for retinal conditions. This initiative will diversify the company\u2019s portfolio. Overall, ALDX ranks 8th on our list of Billionaire Joseph Edelman\u2019s long-term stock picks. While we acknowledge the potential of ALDX as an investment, our conviction lies in the belief that some stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for a stock that is more promising than ALDX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock . READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap Disclosure: None. This article is originally published at Insider Monkey . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ALDX", "date": "2025-01-20T23:28:12", "sentiment": {"score": 0.2610395336523652, "confidence": 0.2709289789199829, "probabilities": {"positive": 0.2709289789199829, "negative": 0.009889445267617702, "neutral": 0.7191816568374634}}, "embedding": [-0.029321279376745224, -0.08996835350990295, -0.06904830038547516, -0.056790612637996674, -0.05177297443151474, -0.0298200361430645, 0.030653970316052437, 0.04482101649045944, 0.10567227005958557, -0.009201861917972565, -0.06974026560783386, 0.14426282048225403, -0.03531529754400253, 0.0013289276976138353, -0.1502177119255066, 0.1454792320728302, 0.0076052965596318245, -0.009705831296741962, -0.1502130627632141, 0.12434200942516327, -0.06898526102304459, -0.12170875072479248, 0.019940130412578583, -0.03704126179218292, -0.002945849671959877, 0.04276980087161064, -0.04890192300081253, -0.007119249552488327, -0.2222958505153656, -0.016835892572999, 0.11446055769920349, 0.07309551537036896, 0.0036555188708007336, -0.06048676744103432, -0.060946106910705566, 0.13475173711776733, -0.03810470551252365, 0.13601502776145935, -0.004876421764492989, -0.00406188378110528, 0.09060832113027573, -0.07621300965547562, -0.07798495888710022, 0.12197983264923096, 0.05087106674909592, -0.2024277150630951, -0.02574913203716278, -0.0014566851314157248, 0.10670633614063263, 0.032495755702257156, -0.3346017301082611, -0.1600704789161682, 0.12471169978380203, -0.1087133139371872, -0.09264203161001205, 0.04460643231868744, -0.027228420600295067, 0.09760725498199463, -0.03691128268837929, 0.0013287067413330078, 0.07347717136144638, -0.11534549295902252, 0.09035433828830719, 0.0375969260931015, 0.0778714120388031, 0.043369509279727936, -0.032015666365623474, 0.010964477434754372, -0.05627718195319176, -0.08462309837341309, 0.1416696012020111, -0.09543491899967194, -0.07277689129114151, 0.05845535546541214, 0.1053251400589943, 0.057286545634269714, 0.056703466922044754, 0.051440633833408356, 0.11529138684272766, -0.11455748975276947, 0.113668292760849, 0.05361749231815338, -0.030322778970003128, 0.016558509320020676, -0.09029816091060638, -0.04513195902109146, -0.017389511689543724, 0.04941411316394806, 0.08956465125083923, 0.07019051164388657, -0.012687690556049347, -0.12118440866470337, -0.05330390855669975, -0.04318328946828842, 0.07493860274553299, 0.014836002141237259, -0.10389754921197891, -0.002207469195127487, -0.1639799177646637, -8.966028690338135e-05, 0.00041262153536081314, 0.033004872500896454, -0.10737964510917664, 0.13236428797245026, -0.07361648976802826, -0.09517496824264526, 0.049160152673721313, 0.032867517322301865, 0.035137761384248734, 0.05041319876909256, -0.1243804395198822, 0.13581228256225586, -0.07206366956233978, 0.06541600078344345, 0.027303460985422134, 0.01578783057630062, -0.0936456024646759, 0.032372139394283295, 0.18344707787036896, -0.029137812554836273, 0.062311604619026184, 0.07317853718996048, -0.0651572197675705, -0.006038326770067215, -0.06305105984210968, -0.05846116691827774, -0.18510952591896057, 1.1078290021639195e-32, -0.09271547198295593, 0.13381469249725342, 0.06666465848684311, 0.1350039839744568, -0.10839502513408661, -0.0035980436950922012, -0.016719656065106392, -0.02417878806591034, -0.11266542971134186, -0.07006479799747467, -0.02469693310558796, 0.1628948450088501, -0.013666389510035515, 0.14781427383422852, -0.054916322231292725, -0.12198759615421295, -0.003429945558309555, 0.048991985619068146, 0.08253652602434158, -0.10184334218502045, -0.032599542289972305, 0.02944774180650711, -0.1322520226240158, -0.058866702020168304, -0.04529934376478195, -0.01273148413747549, 0.009801461361348629, 0.06484159827232361, 0.0073329973965883255, 0.0564839169383049, -0.0273892879486084, 0.08219271898269653, -0.09023785591125488, -0.13810347020626068, 0.018365252763032913, -0.058192178606987, -0.10894592106342316, -0.11553975939750671, 0.09891422837972641, 0.03204219043254852, -0.10846033692359924, 0.15777581930160522, 0.05404681712388992, -0.01575462892651558, -0.10042435675859451, 0.06860892474651337, 0.07384566962718964, 0.16332924365997314, 0.11000585556030273, -0.10289962589740753, -0.017037387937307358, -0.007813723757863045, 0.02623337134718895, -0.13347342610359192, -0.01463437732309103, 0.061617009341716766, -0.12813039124011993, -0.04164005070924759, -0.01480930857360363, 0.04492374509572983, -0.011783547699451447, 0.10816827416419983, -0.08656100928783417, 0.16912759840488434, -0.10893919318914413, 0.10413171350955963, 0.0036240313202142715, -0.01735762506723404, 0.027647942304611206, 0.19719356298446655, -0.03118373639881611, 0.018758010119199753, 0.14315783977508545, -0.07965975254774094, -0.0945839136838913, -0.07330024242401123, -0.03795634210109711, 0.06741496920585632, -0.017733531072735786, 0.08800304681062698, 0.10838726162910461, 0.0005188006907701492, 0.008984096348285675, -0.022020533680915833, -0.05470718815922737, 0.05196421593427658, -0.009587078355252743, 0.029778115451335907, 0.0622384287416935, 0.060247693210840225, 0.030163880437612534, -0.052849624305963516, 0.022702161222696304, 0.06839892268180847, -0.03913485258817673, -1.0627772260794953e-32, -0.11440834403038025, -0.1528819501399994, 0.07412294298410416, -0.08730624616146088, 0.08256927877664566, -0.014212977141141891, 0.023263100534677505, -0.005711324512958527, 0.06867963820695877, -0.06726710498332977, 0.027326075360178947, 0.07802906632423401, -0.013025757856667042, -0.06169595569372177, -0.10749723017215729, 0.051917869597673416, -0.055438533425331116, -0.13916492462158203, -0.043312281370162964, -0.13882315158843994, 0.051492828875780106, 0.1662522554397583, -0.14715576171875, 0.10975289344787598, -0.06717433780431747, 0.09305307269096375, 0.04490170255303383, 0.12837660312652588, 0.008331360295414925, -0.021120259538292885, -0.07561691105365753, 0.013053632341325283, -0.2286345362663269, 0.03501121699810028, -0.024942925199866295, 0.08251400291919708, -0.08787813782691956, -0.17078137397766113, -0.034435879439115524, -0.01642438769340515, 0.10507869720458984, -0.009072422981262207, -0.0035475939512252808, -0.09860648214817047, 0.10608619451522827, 0.08971945941448212, 0.014279237017035484, 0.0888260006904602, 0.1170501559972763, -0.0027723563835024834, -0.0724944919347763, 0.15909159183502197, -0.003747544251382351, 0.016158102080225945, -0.023207247257232666, -0.07076480239629745, 0.12619003653526306, 0.007749713025987148, 0.062221236526966095, -0.0633884146809578, -0.004544340074062347, 0.09703957289457321, 0.10090218484401703, 0.07606595754623413, -0.17635953426361084, -0.01991414651274681, 0.02408607490360737, -0.017487332224845886, -0.09076222777366638, -0.06178165227174759, 0.06875515729188919, -0.0694139376282692, 0.011471889913082123, -0.18805497884750366, -0.04031088948249817, 0.18553104996681213, -0.1384398639202118, -0.14408496022224426, -0.12429624050855637, 0.05073672533035278, 0.013604795560240746, -0.07633714377880096, 0.007932089269161224, 0.11878611147403717, 0.0666198804974556, 0.1135062724351883, 0.013946120627224445, -0.045677825808525085, -0.06572525203227997, -0.052467942237854004, 0.012706637382507324, -0.17558062076568604, -0.12703415751457214, 0.04121042788028717, -0.006042978726327419, -1.0042526810138952e-07, 0.04439695551991463, -0.05971137434244156, 0.07083959877490997, -0.11199989914894104, 0.011058847419917583, -0.01695857383310795, -0.058919697999954224, 0.06570134311914444, 0.12442906200885773, 0.13871558010578156, 0.013237073086202145, 0.08639195561408997, -0.14433695375919342, 0.08788721263408661, -0.03811332583427429, -0.06439123302698135, 0.028768248856067657, -0.017097409814596176, -0.006773833185434341, 0.017844971269369125, 0.07080966234207153, 0.10490567982196808, 0.03447170555591583, -0.04327588900923729, 0.06662577390670776, -0.01686977781355381, 0.017840951681137085, -0.00012267380952835083, -0.0010215132497251034, 0.1288425624370575, 0.014422490261495113, -0.09066920727491379, 0.054944951087236404, -0.04323957860469818, 0.06407421082258224, -0.016237204894423485, 0.09079183638095856, 0.03699134290218353, 0.06115630269050598, 0.10690338909626007, -0.01661919429898262, -0.014774559065699577, 0.07381801307201385, 0.06317897140979767, -0.033833928406238556, -0.04935889691114426, -0.08865578472614288, 0.044044386595487595, 0.10015325248241425, -0.04697706177830696, 0.08585748821496964, -0.061736512929201126, -0.006071034818887711, -0.04473237693309784, 0.005456308834254742, 0.0077120400965213776, -0.05253356695175171, -0.09795454144477844, -0.13502632081508636, 0.027114182710647583, 0.1359870731830597, -0.11501513421535492, 0.07477115094661713, 0.06746166199445724], "changes": {"1wk": 2.8629927841566802}}, {"text": "LIVE The latest news and updates on Trump's tariffs Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock? Zacks Equity Research Mon, Dec 9, 2024, 6:05 PM 2 min read In This Article: ALDX -1.34% Investors in Aldeyra Therapeutics, Inc. ALDX need to pay close attention to the stock based on moves in the options market lately. That is because the March 3, 2025 $2.50 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy. What do the Analysts Think? Clearly, options traders are pricing in a big move for Aldeyra Therapeutics shares, but what is the fundamental picture for the company? Currently, Aldeyra Therapeutics is a Zacks Rank #3 (Hold) in the Medical \u2013 Drugs industry that ranks in the Top 29% of our Zacks Industry Rank. Over the last 60 days, two analysts have increased their earnings estimates for the current quarter, while two have dropped their estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from an earnings of 16 cents per share to loss of 25 cents in that period. Given the way analysts feel about Aldeyra Therapeutics right now, this huge implied volatility could mean there\u2019s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected. Looking to Trade Options? Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners. In addition to impressive profit potential, these trades can actually reduce your risk. Click to see the trades now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Aldeyra Therapeutics, Inc. (ALDX) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ALDX", "date": "2024-12-09T18:05:00", "sentiment": {"score": -0.10768038034439087, "confidence": 0.2171538919210434, "probabilities": {"positive": 0.10947351157665253, "negative": 0.2171538919210434, "neutral": 0.6733726263046265}}, "embedding": [-0.1450655162334442, -0.08099855482578278, 0.05299871414899826, -0.015697792172431946, -0.022138820961117744, -0.043601080775260925, -0.012282760813832283, 0.04380827397108078, 0.12814843654632568, 0.019541099667549133, -0.06037536635994911, 0.15384146571159363, -0.03632160276174545, 0.05694350600242615, -0.010038016363978386, 0.10192374885082245, 0.046738069504499435, -0.11753004789352417, -0.20060011744499207, 0.1896980106830597, -0.03720893710851669, -0.028234651312232018, -0.0724317878484726, -0.005068165250122547, 0.049312181770801544, 0.06688622385263443, -0.0789431780576706, 0.011972571723163128, -0.1269148290157318, -0.032550960779190063, -0.019330793991684914, 0.12390130758285522, -0.0733032077550888, -0.12424886226654053, -0.1089082658290863, -0.058352623134851456, -0.08348169177770615, 0.06722937524318695, 0.09438996016979218, 0.02429995685815811, -0.007281184196472168, 0.0050173308700323105, -0.14363130927085876, 0.10835573822259903, -0.12543490529060364, -0.14357662200927734, 0.12022548913955688, -0.009313931688666344, 0.02918213978409767, 0.03709563985466957, -0.12131109088659286, -0.05271033197641373, 0.043110258877277374, 0.0004729973152279854, -0.0644361674785614, -0.10502650588750839, -0.08190612494945526, 0.0068045868538320065, 0.08676551282405853, 0.02708328142762184, 0.04847747087478638, 0.0820518434047699, 0.03379368409514427, 0.02924947813153267, -0.0415569543838501, 0.0057784393429756165, 0.05759180337190628, 0.03678596019744873, -0.013134803622961044, 0.05089202895760536, 0.10054951906204224, -0.05896638333797455, -0.1356028914451599, 0.01944899559020996, 0.052312735468149185, 0.04834871366620064, 0.10826277732849121, -0.10769481211900711, 0.029804140329360962, 0.012305674143135548, 0.06476889550685883, -0.018273664638400078, 0.001193225383758545, 0.07897625118494034, -0.015378840267658234, -0.08984918892383575, 0.028821002691984177, 0.05297686904668808, 0.09748589992523193, -0.07899370044469833, 0.018438974395394325, -0.0933486670255661, -0.15840867161750793, -0.014906451106071472, 0.10546530783176422, 0.12666365504264832, -0.08079993724822998, 0.03607753664255142, -0.12151788920164108, 0.07518694549798965, 0.0565316379070282, -0.05166852846741676, -0.10430935025215149, -0.0752103254199028, -0.035963431000709534, -0.11489212512969971, 0.06336378306150436, -0.0159777719527483, -0.035829536616802216, 0.06700323522090912, -0.07603772729635239, 0.03397318720817566, -0.09461960196495056, -0.010800554417073727, -0.15559121966362, 0.13206128776073456, 0.010583816096186638, -0.0703340619802475, 0.018888313323259354, 0.013166697695851326, 0.01529850997030735, 0.11945007741451263, 0.010479670949280262, 0.00035726185888051987, 0.007389728911221027, 0.07009892165660858, -0.13499358296394348, 1.2768998403639107e-32, -0.13194744288921356, 0.006408495828509331, 0.02148004062473774, -0.0018770210444927216, -0.00953245721757412, -0.025547003373503685, -0.048924483358860016, -0.04211970791220665, -0.03788462653756142, -0.004377035889774561, -0.1492532193660736, 0.08642186969518661, -0.001385689014568925, 0.061839550733566284, 0.03267200291156769, -0.06724801659584045, 0.006067494861781597, -0.024790532886981964, 0.03951512649655342, -0.058531343936920166, 0.09616442769765854, 0.01552405022084713, -0.09562581777572632, -0.02749667316675186, -0.06011281907558441, 0.09667809307575226, 0.03354673832654953, -0.02515241876244545, -0.05848030000925064, -0.003947042394429445, -0.12191438674926758, 0.06691946089267731, -0.06411130726337433, -0.12181414663791656, 0.02154645510017872, 0.061989933252334595, -0.0622471421957016, -0.018218258395791054, 0.07766582816839218, -0.004441320896148682, -0.002853239653632045, 0.1001340001821518, -0.1629728376865387, 0.08011692762374878, 0.10745184123516083, 0.06418405473232269, -0.10835790634155273, 0.12154078483581543, -0.06363166868686676, 0.009841923601925373, 0.0334337092936039, 0.021687785163521767, -0.0007020551711320877, -0.010639848187565804, -0.11918742954730988, 0.08086072653532028, -0.09745022654533386, -0.08970297873020172, 0.04988160729408264, 0.09173756837844849, 0.07224290817975998, 0.005496407859027386, 0.04990176111459732, 0.022116608917713165, -0.1109408587217331, 0.0600728914141655, -0.03604491055011749, -0.05825047940015793, -0.035414502024650574, 0.03181018307805061, -0.08114100247621536, 0.030874131247401237, 0.17471586167812347, -0.14947457611560822, 0.005275582894682884, -0.07362956553697586, 0.028881307691335678, 0.0024323156103491783, 0.1406497210264206, -0.0018174517899751663, 0.079286590218544, -0.1828126311302185, 0.09078671038150787, -0.024710532277822495, -0.03866036608815193, -0.10313504934310913, -0.13802039623260498, -0.022369910031557083, -0.08492320775985718, 0.05946806073188782, 0.025186801329255104, 0.047781843692064285, -0.0398266576230526, 0.04033951088786125, 0.08756884932518005, -1.391742699703371e-32, -0.06743372976779938, -0.07491894066333771, 0.07718367129564285, -0.05402360111474991, 0.10214482992887497, 0.07103203237056732, 0.04781413823366165, 0.03981311246752739, 0.03544459864497185, -0.07668646425008774, -0.024694284424185753, 0.1070123091340065, -0.06651604920625687, 0.06550967693328857, -0.04250697046518326, -0.024171680212020874, 0.046322211623191833, -0.12731999158859253, 0.09974052011966705, -0.09256439656019211, -0.040950044989585876, 0.16733849048614502, -0.25654780864715576, 0.12533943355083466, 0.03233123570680618, 0.02730017527937889, 0.012159086763858795, 0.056919023394584656, 0.0835852101445198, 0.04662568122148514, -0.11934539675712585, 0.05627038702368736, -0.11756010353565216, 0.04091303423047066, 0.09130220115184784, 0.13933376967906952, 0.08299875259399414, -0.002010166645050049, -0.10553517937660217, -0.003010324202477932, 0.050119686871767044, -0.03542783111333847, 0.011587541550397873, 0.012482943944633007, 0.07621986418962479, 0.16179563105106354, 0.05168268084526062, 0.023752829059958458, 0.14241449534893036, -0.029608115553855896, 0.06840798258781433, 0.09518727660179138, -0.08100652694702148, 0.16933968663215637, 0.04858947545289993, -0.06726953387260437, -0.07021057605743408, -0.10833004117012024, 0.008535538800060749, 0.02369185909628868, 0.03105168044567108, 0.1682453453540802, 0.0939733013510704, -0.12967832386493683, -0.03139931708574295, 0.029891712591052055, -0.07663625478744507, -0.10363485664129257, -0.0691525936126709, -0.06122966855764389, 0.08211131393909454, -0.11039292812347412, -0.09594607353210449, -0.12114053964614868, 0.07455100864171982, 0.08498748391866684, 0.010080285370349884, -0.1537954956293106, -0.07182973623275757, -0.030575020238757133, 0.034901585429906845, -9.761471301317215e-05, 0.014028700068593025, 0.004707928281277418, -0.07357209175825119, 0.1269892007112503, -0.08720450848340988, 0.12985405325889587, -0.0550791434943676, 0.004142905119806528, -0.05160330608487129, -0.14900687336921692, -0.13285952806472778, 0.02863607183098793, -0.038008447736501694, -1.0016183438210646e-07, 0.016811545938253403, -0.0032313065603375435, 0.055657338351011276, -0.06417788565158844, -0.025201920419931412, 0.03919072821736336, 0.026866529136896133, 0.10155770927667618, 0.17904992401599884, 0.1278723180294037, 0.22262367606163025, 0.07790542393922806, -0.10416288673877716, -0.0018182359635829926, -0.02444847673177719, 0.10734038054943085, -0.08910560607910156, -0.01782727800309658, -0.021096084266901016, -0.00515713170170784, -0.03249002620577812, 0.05726400390267372, 0.07848402857780457, -0.09624400734901428, 0.11460703611373901, -0.03415074571967125, -0.08315446972846985, 0.09954822063446045, -0.00016883015632629395, 0.11743713915348053, 0.007229193113744259, -0.029974540695548058, -0.0008850675076246262, 0.06238062307238579, -0.033624038100242615, 0.02293858304619789, 0.03992711380124092, 0.04821554198861122, 0.048205673694610596, -0.05575995892286301, -0.0569973960518837, -0.09901569783687592, 0.00030141836032271385, -0.061672475188970566, -0.005464101210236549, -0.10590183734893799, -0.015694253146648407, -0.005162329878658056, 0.11880460381507874, -0.020312625914812088, 0.026404233649373055, -0.07639781385660172, 0.055416978895664215, 0.05824866518378258, 0.023633740842342377, 0.029854103922843933, -0.11191011965274811, -0.10469447821378708, -0.08879632502794266, -0.0024657328613102436, 0.08404400944709778, -0.16638830304145813, 0.015291934832930565, 0.1992804855108261], "changes": {"1wk": -3.2504794583932224, "1mo": -2.294452870391011}}, {"text": "LIVE The latest news and updates on Trump's tariffs ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap Zacks Equity Research Tue, Nov 19, 2024, 6:00 PM 4 min read In This Article: ALDX -1.34% ABBV +3.39% Aldeyra Therapeutics, Inc. ALDX announced that the FDA has accepted its resubmitted new drug application (NDA) for reproxalap, a first-in-class investigational RASP modulator, for the treatment of the signs and symptoms of dry eye disease. With the FDA accepting the resubmitted NDA for review, a decision from the regulatory body is expected on April 2, 2025. Simultaneously, Aldeyra announced that it has expanded its existing option agreement with AbbVie ABBV. Shares of Aldeyra were up 11.6% on Nov. 18 following the announcement of the news. The stock has rallied 33.9% so far this year against the industry\u2019s decline of 6%. Zacks Investment Research Image Source: Zacks Investment Research More on ALDX's NDA Resubmission of Reproxalap We remind investors that in November 2023, Aldeyra received a complete response letter (CRL) from the FDA for its NDA of reproxalap to treat dry eye disease. Per the FDA, the study results supporting the NDA failed to demonstrate reproxalap\u2019s efficacy in treating ocular symptoms associated with dry eyes, which formed the basis of the CRL issue. Back then, the FDA had recommended that at least one additional adequate and well-controlled study should be conducted on reproxalap to demonstrate a positive effect on the treatment of ocular symptoms of dry eye. Following this, Aldeyra decided to initiate a dry eye chamber clinical study to address the issues stated by the FDA in the CRL. In May, ALDX enrolled the first patient in a phase III dry eye chamber study, which was designed to ensure a potential resubmission of NDA for reproxalap for treating dry eye disease. In August, the company announced that the phase III dry eye chamber study, which evaluated reproxalap for the treatment of dry eye disease met the primary endpoint. In the study, treatment with reproxalap was statistically superior to vehicle for the prespecified primary endpoint of ocular discomfort, an FDA-accepted symptom of dry eye disease. Aldeyra resubmitted the NDA for reproxalap for treating signs and symptoms of dry eye disease last month. ALDX's Option Agreement With AbbVie Under the latest expanded option agreement, Aldeyra will begin certain pre-commercial activities, for which 40% will be paid by the company, and the remaining 60% will be borne by ABBV if the option is exercised. AbbVie too has independently started pre-commercial planning activities. We remind investors that, in October 2023, Aldeyra entered into an exclusive option agreement with AbbVie, which granted the latter an option to acquire a co-exclusive license to develop, manufacture and commercialize reproxalap within the United States and an exclusive license for the same outside the United States. Story Continues If ABBV chooses to exercise the option, ALDX will be eligible to receive an upfront payment of $100 million less option fees of $6 million, which was previously paid. Additionally, Aldeyra is eligible to receive up to $300 million in regulatory and commercial milestone payments from AbbVie, including a $100 million milestone payment payable upon the potential FDA approval for reproxalap. Aldeyra and AbbVie will share U.S. profits and losses received in connection with the commercialization of reproxalap. While Aldeyra would receive 40% of the profits, ABBV would receive the remaining 60%. ALDX's Zacks Rank & Key Picks Aldeyra currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the biotech sector are Immunocore Holdings plc IMCR and Castle Biosciences, Inc. CSTL, each carrying a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here . In the past 60 days, estimates for Immunocore\u2019s 2024 loss per share have narrowed from $1.79 to 94 cents. Loss per share estimates for 2025 have narrowed from $2.35 to $1.57 during the same time. Year to date, shares of IMCR have declined 54.6%. IMCR\u2019s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 25.57%. In the past 60 days, estimates for Castle Biosciences\u2019 2024 loss per share have narrowed from 58 cents to 8 cents. Loss per share estimates for 2025 have narrowed from $2.13 to $1.88 during the same time. Year to date, shares of CSTL have surged 29.3%. CSTL\u2019s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AbbVie Inc. (ABBV) : Free Stock Analysis Report Aldeyra Therapeutics, Inc. (ALDX) : Free Stock Analysis Report Castle Biosciences, Inc. (CSTL) : Free Stock Analysis Report Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ALDX", "date": "2024-11-19T18:00:00", "sentiment": {"score": 0.8291850304231048, "confidence": 0.8385909199714661, "probabilities": {"positive": 0.8385909199714661, "negative": 0.009405889548361301, "neutral": 0.152003213763237}}, "embedding": [-0.07637335360050201, -0.16129723191261292, 0.029456820338964462, 0.03440345823764801, -0.03933223336935043, -0.0006294678896665573, -0.025288410484790802, 0.11287006735801697, -0.003890609834343195, 0.057530686259269714, -0.053261302411556244, 0.14337588846683502, 0.010237540118396282, 0.022256210446357727, -0.01638738624751568, 0.10032707452774048, 0.09843720495700836, -0.10896294564008713, -0.18965893983840942, 0.1455187201499939, 0.13346344232559204, -0.060982830822467804, 0.08355576545000076, 0.03445375710725784, -0.02692529745399952, 0.0339779295027256, -0.0936933308839798, -0.02600259706377983, -0.06713707745075226, -0.15074153244495392, 0.028960352763533592, 0.21678465604782104, -0.05218743532896042, -0.15601229667663574, -0.04589933156967163, -0.0984969437122345, -0.12295687198638916, -0.03268759697675705, -0.115606889128685, 0.07127675414085388, 0.01948489248752594, -0.013438445515930653, -0.20056600868701935, 0.10798995941877365, 0.020632661879062653, -0.1868656873703003, 0.04648442566394806, 0.1352231204509735, 0.05756857246160507, 0.16376912593841553, -0.12230834364891052, -0.13762745261192322, 0.04134339839220047, 0.039990633726119995, -0.07154762744903564, 0.019420132040977478, -0.1923108547925949, -0.08060630410909653, 0.12383419275283813, 0.02749444916844368, 0.08198857307434082, -0.010838470421731472, -0.02240421064198017, 0.04608462378382683, 0.037478577345609665, 0.04356967285275459, 0.001167410984635353, -0.2026709020137787, -0.016267213970422745, -0.08227422088384628, 0.020134996622800827, -0.11077659577131271, 0.04969755560159683, 0.014393708668649197, -0.0872049480676651, 0.07342301309108734, 0.20356819033622742, -0.06758587062358856, 0.13763955235481262, -0.03325245901942253, 0.09171724319458008, 0.11516512930393219, 0.14322951436042786, -0.023602750152349472, 0.03111818991601467, -0.04042584449052811, 0.03749353811144829, 0.09307568520307541, 0.02312571182847023, -0.06143488734960556, 0.09837059676647186, -0.03428255766630173, 0.0031470227986574173, -0.014635059982538223, -0.004359956830739975, 0.04681898653507233, -0.060764580965042114, -0.01394294761121273, -0.06157169118523598, 0.019759278744459152, 0.0751960352063179, -0.03037526085972786, -0.06942954659461975, -0.11286020278930664, -0.11098390817642212, -0.10228231549263, 0.08461325615644455, -0.0009198845364153385, -0.04340623319149017, 0.020644795149564743, -0.1122080385684967, 0.08145172148942947, 0.03107098862528801, 0.0078045278787612915, -0.11951092630624771, 0.14328360557556152, -0.12855257093906403, -0.09787920862436295, 0.14747685194015503, -0.12242257595062256, 0.09403672814369202, -0.015673188492655754, 0.09454551339149475, -0.06629765033721924, 0.1389119029045105, 0.03291512653231621, -0.04926016554236412, 1.3663280710282117e-32, -0.11006950587034225, -0.0018996833823621273, -0.12199822068214417, -0.011562405154109001, 0.028520651161670685, -0.0235359575599432, 0.02478889934718609, 0.08915122598409653, -0.1685847043991089, -0.14446169137954712, -0.09580495953559875, 0.0636366531252861, -0.0073449499905109406, 0.13937802612781525, -0.10253092646598816, -0.08211322873830795, -0.012887617573142052, 0.07437074184417725, 0.032684121280908585, -0.03423786163330078, -0.04911074787378311, 0.032578252255916595, -0.0860479548573494, 0.07237741351127625, -0.11235612630844116, 0.11168821156024933, -0.033770110458135605, 0.05021167919039726, -0.004622956737875938, 0.031115852296352386, 0.04515234753489494, 0.10278366506099701, 0.020451614633202553, -0.0980781763792038, -0.04706346243619919, 0.0022863075137138367, -0.08166481554508209, -0.08698399364948273, -0.07649217545986176, -0.019952567294239998, 0.034022312611341476, 0.2500002980232239, -0.08374324440956116, -0.03844428434967995, 0.13541150093078613, -0.006167999468743801, -0.19469496607780457, 0.0979340523481369, -0.00963631086051464, -0.06077199801802635, 0.046680085361003876, 0.11118356883525848, -0.01262592151761055, -0.1630784273147583, -0.09816659986972809, 0.08354677259922028, -0.17745555937290192, -0.09510686993598938, 0.04836282879114151, 0.07974958419799805, -0.014697806909680367, 0.08549020439386368, 0.028045937418937683, 0.016629314050078392, -0.23452121019363403, 0.12531301379203796, 0.008264588192105293, -0.08326338231563568, -0.14870864152908325, -0.04338289424777031, -0.018616555258631706, 0.035975873470306396, 0.1695089489221573, -0.007096000947058201, 0.08111701905727386, -0.11695262789726257, 0.09781098365783691, 0.06451015174388885, 0.10880930721759796, -0.041999850422143936, 0.05923759192228317, -0.010923461988568306, 0.10976720601320267, 0.043253667652606964, -0.02922031469643116, -0.11678143590688705, -0.04960622638463974, 0.04614283889532089, -0.032766107469797134, -0.0760958194732666, 0.1377021074295044, 0.032846599817276, -0.064639613032341, 0.05156823992729187, 0.23090791702270508, -1.424832424868637e-32, -0.021247025579214096, -0.07111389189958572, 0.02745429240167141, -0.051198214292526245, -0.01980273425579071, 0.11714229732751846, 0.14024877548217773, -0.01760214753448963, 0.18485039472579956, -0.12640328705310822, 0.1570427119731903, 0.05741768702864647, -0.08342745155096054, -0.028213873505592346, -0.04417312890291214, 0.013577183708548546, 0.010881340131163597, -0.13086697459220886, -0.05332399159669876, 0.04721344634890556, 0.08206893503665924, 0.14278152585029602, -0.0008789073908701539, 0.05761216953396797, 0.08206047117710114, 0.011489015072584152, 0.10888773202896118, -0.01422404870390892, 0.09265623986721039, -0.05226854607462883, -0.011039460077881813, 0.00274658203125, -0.2870209813117981, 0.057368598878383636, -0.0346178263425827, 0.010517114773392677, 0.005854226183146238, -0.1565493494272232, -0.17919932305812836, -0.0651310384273529, 0.20237314701080322, 0.0312266256660223, -0.03144631162285805, -0.07554838806390762, 0.10253924131393433, 0.043580763041973114, 0.04222795367240906, -0.09463029354810715, 0.15239620208740234, -0.04393953084945679, -0.011523563414812088, 0.02200157754123211, 0.01877979002892971, 0.0626019686460495, 0.02288287878036499, 0.09174497425556183, 0.11640328168869019, -0.013214308768510818, -0.0027039479464292526, 0.09178920090198517, -0.0567232221364975, 0.16611838340759277, 0.08360686898231506, -0.11664395779371262, 0.06208010017871857, 0.02660316973924637, 0.0024892576038837433, 0.0037037208676338196, 0.15875425934791565, -0.09038310497999191, 0.03100116178393364, -0.09613846987485886, -0.16038508713245392, -0.07169736921787262, -0.0029957150109112263, 0.17749133706092834, -0.047295670956373215, -0.10097859799861908, -0.22612226009368896, 0.045082297176122665, 0.0018781470134854317, 0.009854150004684925, 0.020997270941734314, 0.10678096860647202, 0.012922622263431549, 0.07026708871126175, 0.04658180847764015, -0.06951823085546494, -0.034057628363370895, 0.09526988863945007, -0.1195337101817131, -0.21804316341876984, -0.10980787873268127, 0.08487206697463989, 0.030655819922685623, -1.0046396425877901e-07, 0.012152327224612236, 0.0040220096707344055, 0.09064288437366486, -0.03231056034564972, 0.08749008178710938, -0.011873288080096245, -0.04536158964037895, 0.04649215564131737, -0.024745093658566475, 0.05313275754451752, 0.0683794617652893, 0.18840178847312927, -0.14327991008758545, 0.09048953652381897, -0.03230264037847519, 0.06025950610637665, 0.020143859088420868, -0.042824722826480865, -0.01879154145717621, -0.10722386837005615, -0.08615037798881531, 0.004850233439356089, 0.07288942486047745, 0.042074598371982574, 0.0527009591460228, -0.020053867250680923, -0.02135624550282955, 0.1037660762667656, -0.023365098983049393, 0.03648986667394638, -0.004174262285232544, -0.008659549057483673, 0.025576656684279442, -0.09123889356851578, -0.005610968917608261, -0.13066288828849792, 0.11028359830379486, 0.16053630411624908, 0.08940006792545319, 0.12539207935333252, -0.04028177633881569, -0.01103269774466753, 0.0696212574839592, 0.0022840481251478195, -0.010149851441383362, -0.06398630887269974, -0.0868101418018341, -0.19494479894638062, 0.05713013559579849, -0.10873287916183472, 0.0942826122045517, -0.1289505511522293, -0.03575477749109268, -0.035518113523721695, -0.06732767820358276, 0.015379685908555984, -0.099512979388237, -0.1369328647851944, -0.0547892227768898, -0.1186855211853981, 0.0358266718685627, -0.10227101296186447, 0.0466599240899086, 0.08452427387237549], "changes": {"1wk": -2.834005361618721, "1mo": -1.6194316352106979}}, {"text": "LIVE The latest news and updates on Trump's tariffs 3 US Penny Stocks With Market Caps Over $80M To Watch editorial-team@simplywallst.com (Simply Wall St) Wed, Jan 1, 2025, 3:09 AM 4 min read In This Article: ALDX -1.34% KNDI -5.41% ANL -4.66% As the U.S. stock market concludes a strong year on a weak note, with major indices like the Dow experiencing significant monthly losses, investors are reflecting on opportunities within various sectors. Penny stocks, often associated with smaller or newer companies, remain an intriguing area for those seeking potential growth despite their somewhat outdated label. By focusing on companies that exhibit solid financial health and promising prospects, investors can uncover potential value in this niche segment of the market. Top 10 Penny Stocks In The United States Name Share Price Market Cap Financial Health Rating BAB (OTCPK:BABB) $0.77 $6.03M \u2605\u2605\u2605\u2605\u2605\u2605 Inter & Co (NasdaqGS:INTR) $4.22 $1.84B \u2605\u2605\u2605\u2605\u2606\u2606 QuantaSing Group (NasdaqGM:QSG) $3.08 $111.43M \u2605\u2605\u2605\u2605\u2605\u2605 Kiora Pharmaceuticals (NasdaqCM:KPRX) $3.30 $9.9M \u2605\u2605\u2605\u2605\u2605\u2605 ZTEST Electronics (OTCPK:ZTST.F) $0.29 $10.49M \u2605\u2605\u2605\u2605\u2605\u2605 CBAK Energy Technology (NasdaqCM:CBAT) $0.94 $97.13M \u2605\u2605\u2605\u2605\u2605\u2606 Imperial Petroleum (NasdaqCM:IMPP) $3.01 $93.12M \u2605\u2605\u2605\u2605\u2605\u2605 Golden Growers Cooperative (OTCPK:GGRO.U) $4.50 $67.38M \u2605\u2605\u2605\u2605\u2605\u2605 BTCS (NasdaqCM:BTCS) $2.47 $43.38M \u2605\u2605\u2605\u2605\u2605\u2605 Smith Micro Software (NasdaqCM:SMSI) $1.31 $24.65M \u2605\u2605\u2605\u2605\u2605\u2606 Click here to see the full list of 733 stocks from our US Penny Stocks screener. Here's a peek at a few of the choices from the screener. Aldeyra Therapeutics Simply Wall St Financial Health Rating: \u2605\u2605\u2605\u2605\u2605\u2605 Overview: Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing and commercializing medicines for immune-mediated diseases, with a market cap of $298.94 million. Operations: Aldeyra Therapeutics, Inc. does not currently report any revenue segments. Market Cap: $298.94M Aldeyra Therapeutics, Inc., a biotechnology company with a market cap of US$298.94 million, is pre-revenue and currently unprofitable but has made strides in reducing losses over the past five years. The company's management and board are experienced, with an average tenure of 3.9 and 11.3 years respectively. Aldeyra's short-term assets significantly exceed its liabilities, providing financial stability despite ongoing losses. Recent developments include the resubmission of a New Drug Application for reproxalap to the FDA after positive Phase 3 trial results for dry eye disease treatment, which could potentially impact future revenue streams if approved. Navigate through the intricacies of Aldeyra Therapeutics with our comprehensive balance sheet health report here. Learn about Aldeyra Therapeutics' future growth trajectory here. NasdaqCM:ALDX Debt to Equity History and Analysis as at Jan 2025 Adlai Nortye Simply Wall St Financial Health Rating: \u2605\u2605\u2605\u2605\u2606\u2606 Overview: Adlai Nortye Ltd. is a clinical-stage biotechnology company dedicated to discovering and developing cancer therapies in the United States and Mainland China, with a market cap of $85.24 million. Story Continues Operations: Adlai Nortye Ltd. has not reported any revenue segments. Market Cap: $85.24M Adlai Nortye Ltd., with a market cap of US$85.24 million, is a pre-revenue biotechnology company focused on cancer therapies. The company has not reported significant revenue and remains unprofitable, with losses increasing at an annual rate of 12.7% over the past five years. Despite this, Adlai Nortye's financial position shows more cash than total debt and short-term assets exceeding liabilities by US$45.98 million, suggesting some level of financial stability. However, high share price volatility and an inexperienced management team may pose challenges to investor confidence in the near term. Click here and access our complete financial health analysis report to understand the dynamics of Adlai Nortye. Review our growth performance report to gain insights into Adlai Nortye's future. NasdaqGM:ANL Debt to Equity History and Analysis as at Jan 2025 Kandi Technologies Group Simply Wall St Financial Health Rating: \u2605\u2605\u2605\u2605\u2606\u2606 Overview: Kandi Technologies Group, Inc. designs, develops, manufactures, and commercializes electric vehicle products and parts in China and the United States with a market cap of approximately $81.49 million. Operations: The company generates revenue primarily from its Auto Manufacturers segment, amounting to $118.13 million. Market Cap: $81.49M Kandi Technologies Group, with a market cap of US$81.49 million, focuses on electric vehicle products and parts. Despite being unprofitable, the company maintains financial stability with short-term assets of US$396.7 million surpassing liabilities and more cash than total debt. Recent earnings showed a net loss of US$4.11 million for Q3 2024, reflecting challenges in profitability compared to the previous year\u2019s net income. The company plans significant U.S.-based expansions in lithium battery manufacturing and all-terrain vehicles production, potentially enhancing revenue streams but also indicating substantial capital investment requirements amidst high share price volatility. Jump into the full analysis health report here for a deeper understanding of Kandi Technologies Group. Evaluate Kandi Technologies Group's historical performance by accessing our past performance report. NasdaqGS:KNDI Financial Position Analysis as at Jan 2025 Turning Ideas Into Actions Access the full spectrum of 733 US Penny Stocks by clicking on this link. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide. Ready For A Different Approach? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Jump on the AI train with fast growing tech companies forging a new era of innovation. Find companies with promising cash flow potential yet trading below their fair value . This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqCM:ALDX NasdaqGM:ANL and NasdaqGS:KNDI . Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ALDX", "date": "2025-01-01T03:09:16", "sentiment": {"score": 0.019901394844055176, "confidence": 0.06200382485985756, "probabilities": {"positive": 0.06200382485985756, "negative": 0.04210243001580238, "neutral": 0.8958937525749207}}, "embedding": [-0.0165448896586895, -0.12596441805362701, -0.0951032042503357, -0.009356602095067501, 0.04961351305246353, 0.026291336864233017, 0.06121709197759628, 0.02914649061858654, 0.012977193109691143, -0.06230089068412781, -0.09141405671834946, -0.027250861749053, -0.03195878118276596, -0.006855844985693693, -0.08127234876155853, -0.03135015815496445, 0.06869638711214066, -0.0008313469588756561, 0.012745341286063194, 0.055730611085891724, -0.13135391473770142, -0.029492471367120743, 0.08093389868736267, 0.07044880092144012, 0.0001785755157470703, 0.05670233443379402, 0.00918491743505001, -0.024711573496460915, -0.22638633847236633, -0.1888633370399475, -0.07324837148189545, 0.02983143739402294, 0.05662013590335846, -0.12853631377220154, -0.048820849508047104, -0.06140093505382538, 0.053398557007312775, 0.09638403356075287, 0.03994401916861534, -0.03589974343776703, 0.013502666726708412, -0.03817175701260567, -0.04530854523181915, 0.04088396579027176, 0.05705305188894272, -0.14062824845314026, -0.025160428136587143, 0.0314512737095356, 0.1637474000453949, 0.019329771399497986, -0.06048797816038132, 0.07837274670600891, 0.061351463198661804, 0.07007438689470291, -0.07451847195625305, -0.00485408678650856, -0.10408336669206619, 0.020911123603582382, 0.0898643285036087, 0.024228105321526527, -0.0049377018585801125, 0.02967401035130024, 0.05346875265240669, 0.010835238732397556, 0.1871340125799179, 0.018561698496341705, -0.11973945051431656, -0.03393746167421341, -0.04781760647892952, -0.1312446892261505, 0.02145085483789444, -0.11665689200162888, -0.11032971739768982, -0.018332350999116898, -0.11275018751621246, 0.10392531007528305, 0.12441790103912354, 0.009068530052900314, 0.07471361756324768, 0.03701096028089523, -0.1153784766793251, -0.05603385716676712, 0.0818345695734024, -0.0074760932475328445, -0.0620269775390625, -0.028252752497792244, 0.0146842822432518, 0.044866226613521576, -0.0025396496057510376, -0.10402867197990417, 0.09288626164197922, 0.012666156515479088, -0.14979490637779236, 0.049439311027526855, -0.025482958182692528, -0.01870323345065117, -0.06206963583827019, 0.0477059967815876, -0.07761292904615402, 0.07889817655086517, 0.21767482161521912, -0.059804338961839676, -0.1088767945766449, -0.06385438144207001, -0.04982960224151611, -0.07715678960084915, 0.09880487620830536, -0.05638899654150009, 0.035104017704725266, 0.055609095841646194, 0.03071559965610504, 0.0915050059556961, -0.1145346462726593, -0.08225081861019135, -0.12184154987335205, -0.05889272317290306, -0.10038259625434875, -0.16705754399299622, 0.16097815334796906, -0.004888012073934078, 0.06759030371904373, 0.06190377473831177, -0.09952045977115631, 0.0017959978431463242, -0.09299717843532562, 0.044398464262485504, -0.034765999764204025, 1.4363638775134097e-32, -0.08928579092025757, 0.045137010514736176, -0.005468898452818394, -0.10719069093465805, -0.08368556946516037, 0.03934982791543007, 0.04280714690685272, -0.08442486077547073, -0.15390276908874512, -0.06148013472557068, -0.109879270195961, 0.093181312084198, -0.05985566973686218, 0.0006670374423265457, -0.06330329179763794, -0.210290789604187, 0.0028618434444069862, 0.013005996122956276, 0.023007335141301155, -0.12502869963645935, -0.02018854208290577, 0.16199716925621033, -0.10485906898975372, 0.05481165274977684, 0.017682405188679695, 0.07451996952295303, -0.0924452692270279, -0.08023813366889954, 0.018729383125901222, 0.08258581161499023, 0.007580997887998819, 0.1330961287021637, 0.008530871942639351, -0.043665193021297455, -0.12434276938438416, -0.04577696695923805, -0.15225762128829956, -0.026909366250038147, -0.008665857836604118, -0.07921751588582993, -0.04533654451370239, 0.1276567280292511, -0.08449457585811615, 0.06925337016582489, 0.02280508726835251, 0.08172248303890228, -0.08362296968698502, 0.173944890499115, 0.0470828115940094, -0.17191556096076965, -0.13266442716121674, -0.01201779954135418, -0.08562257885932922, 0.03774118050932884, -0.02009952813386917, 0.041110746562480927, -0.02540920302271843, -0.16241443157196045, 0.02791859209537506, 0.09844905138015747, 0.02788006328046322, 0.14949917793273926, -0.10324430465698242, 0.0016225799918174744, -0.15899062156677246, 0.1330920159816742, 0.03843638673424721, 0.08620285242795944, -0.11137133091688156, 0.18353420495986938, -0.01815740205347538, -0.005045960191637278, 0.22831793129444122, 0.0778978019952774, 0.11312711983919144, -0.017046313732862473, 0.028942996636033058, 0.01718509942293167, 0.023838991299271584, -0.05956371873617172, 0.02533450908958912, -0.0916680172085762, 0.041681934148073196, 0.06277759373188019, 0.006116582080721855, -0.03338535875082016, -0.06921958923339844, 0.04799879342317581, -0.026625826954841614, -0.07452154159545898, -0.0006918162107467651, -0.009639368392527103, 0.04243658110499382, 0.031950853765010834, -0.11028953641653061, -1.581988819670678e-32, -0.0035305405035614967, -0.02612806111574173, 0.0033848192542791367, -0.03680267184972763, -0.034013308584690094, -0.00923303235322237, 0.018171139061450958, -0.04996009171009064, 0.025601549074053764, -0.013334970921278, -0.0193135067820549, 0.022516414523124695, -0.014684030786156654, 0.03475650027394295, -0.05227304995059967, 0.12124130129814148, -0.009976984933018684, -0.02156246453523636, 0.017018545418977737, -0.1118236780166626, -0.09806808829307556, 0.1518690586090088, -0.16884323954582214, 0.08679267764091492, -0.008474865928292274, 0.004737899638712406, -0.01725168526172638, 0.058642998337745667, 0.07022680342197418, 0.05022815987467766, -0.1104830950498581, 0.045227423310279846, -0.10553678870201111, 0.09005133807659149, -0.06221163645386696, 0.09037043899297714, 0.06659044325351715, -0.07507210224866867, -0.039495065808296204, 0.06158675625920296, 0.04562702029943466, -0.038245007395744324, 0.015553055331110954, 0.034743767231702805, 0.09719568490982056, 0.01953217014670372, -0.021003231406211853, 0.030971292406320572, 0.030925489962100983, 0.12407489120960236, 0.02013324201107025, 0.06968183815479279, 0.07877030223608017, 0.10489537566900253, -0.17796072363853455, 0.06934073567390442, -0.02512916550040245, 0.041712649166584015, -0.07536566257476807, -0.05916132032871246, 0.015835661441087723, 0.17294906079769135, 0.11728755384683609, 0.046813659369945526, -0.036379262804985046, 0.016127729788422585, -0.06794511526823044, 0.06563795357942581, -0.06178770214319229, -0.09216545522212982, -0.010783796198666096, -0.06686268746852875, 0.13689973950386047, -0.16159588098526, -0.031649477779865265, 0.17760103940963745, -0.04000765085220337, 0.022943934425711632, -0.008157696574926376, 0.1612800657749176, 0.03812113031744957, 0.09319205582141876, 0.04669374227523804, 0.06903780251741409, 0.05124630779027939, 0.11497186124324799, 0.0012527210637927055, 0.035568948835134506, -0.028512591496109962, 0.01160351000726223, -0.06095467507839203, -0.10800373554229736, -0.04720412194728851, -0.0042535471729934216, -0.08480103313922882, -1.0038388609245885e-07, 0.06851902604103088, -0.08343459665775299, -0.01765509322285652, -0.003937987610697746, 0.04627566784620285, 0.05487845093011856, 0.026372142136096954, 0.037635087966918945, -0.004578665364533663, 0.15385138988494873, 0.1312541514635086, 0.09508964419364929, -0.22322864830493927, -0.005265961401164532, -0.10329685360193253, -0.006471474189311266, -0.007506218738853931, 0.1130814179778099, 0.002302795648574829, -0.0006661294028162956, 0.03488674387335777, 0.1693001091480255, 0.12914475798606873, -0.06804368644952774, 0.013585194945335388, 0.047174952924251556, -0.06980647891759872, -0.0009945901110768318, 0.07646319270133972, 0.07461807131767273, -0.006394305266439915, 0.008599956519901752, 0.02693401463329792, -0.07057439535856247, 0.11317883431911469, 0.05717082694172859, -0.07282166182994843, 0.10686905682086945, 0.0293983593583107, 0.06694087386131287, -0.042716581374406815, -0.09266682714223862, 0.005161663051694632, -0.017478937283158302, 0.06674998998641968, -0.09000267833471298, -0.1677251160144806, 0.03582916408777237, 0.17346160113811493, -0.1869637370109558, -0.013155819848179817, -0.04849131405353546, -0.04597797617316246, 0.012911083176732063, 0.03774551302194595, 0.13340100646018982, -0.1804439127445221, -0.017738549038767815, -0.11331432312726974, -0.0364709347486496, 0.0931689515709877, -0.24173378944396973, 0.08253017067909241, 0.18404778838157654], "changes": {"1wk": -2.10727320112033, "1mo": 3.44828184694568}}, {"text": "LIVE The latest news and updates on Trump's tariffs High Growth Tech Stocks To Watch In December 2024 editorial-team@simplywallst.com (Simply Wall St) Fri, Dec 20, 2024, 9:02 PM 4 min read In This Article: AKBA -5.36% ALDX -1.34% INFN +0.15% Over the last 7 days, the United States market has dropped 3.5%, yet it remains up by 22% over the past year with earnings forecasted to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these positive earnings forecasts despite recent market volatility. Top 10 High Growth Tech Companies In The United States Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 23.95% 24.32% \u2605\u2605\u2605\u2605\u2605\u2605 Ardelyx 25.47% 69.63% \u2605\u2605\u2605\u2605\u2605\u2605 Sarepta Therapeutics 23.98% 42.48% \u2605\u2605\u2605\u2605\u2605\u2605 Alnylam Pharmaceuticals 22.34% 70.30% \u2605\u2605\u2605\u2605\u2605\u2605 Clene 77.61% 59.19% \u2605\u2605\u2605\u2605\u2605\u2605 TG Therapeutics 34.86% 56.98% \u2605\u2605\u2605\u2605\u2605\u2605 Alkami Technology 21.99% 102.65% \u2605\u2605\u2605\u2605\u2605\u2605 Travere Therapeutics 31.70% 72.51% \u2605\u2605\u2605\u2605\u2605\u2605 Seagen 22.57% 71.80% \u2605\u2605\u2605\u2605\u2605\u2605 ImmunoGen 26.00% 45.85% \u2605\u2605\u2605\u2605\u2605\u2605 Click here to see the full list of 237 stocks from our US High Growth Tech and AI Stocks screener. Let's explore several standout options from the results in the screener. Akebia Therapeutics Simply Wall St Growth Rating: \u2605\u2605\u2605\u2605\u2605\u2606 Overview: Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutics for kidney disease patients, with a market cap of approximately $384 million. Operations: Akebia Therapeutics generates revenue primarily from developing and commercializing novel therapeutics for kidney disease, amounting to $169.88 million. Akebia Therapeutics, despite being unprofitable, shows promise with a forecasted annual revenue growth of 27.1%, significantly outpacing the US market's 9.1%. This growth is underpinned by its recent FDA approval of Vafseo for treating anemia in dialysis patients, a significant milestone expected to drive future revenues upon its January 2025 launch. The company's strategic engagement at key healthcare conferences and the initiation of the VOICE trial underscore its commitment to solidifying Vafseo\u2019s market position. However, challenges remain with a net loss widening this quarter compared to last year, emphasizing the need for careful monitoring of its financial health as it scales operations. Take a closer look at Akebia Therapeutics' potential here in our health report. Examine Akebia Therapeutics' past performance report to understand how it has performed in the past. NasdaqCM:AKBA Earnings and Revenue Growth as at Dec 2024 Aldeyra Therapeutics Simply Wall St Growth Rating: \u2605\u2605\u2605\u2605\u2605\u2606 Overview: Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing and commercializing medicines for immune-mediated diseases, with a market cap of $290.60 million. Operations: Aldeyra Therapeutics specializes in creating and marketing treatments for immune-mediated diseases. With a market capitalization of approximately $290.60 million, the company is positioned within the biotechnology sector. Story Continues Aldeyra Therapeutics has demonstrated a robust commitment to innovation in the biotech sector, particularly with its recent advancements in dry eye disease treatments. The company's resubmission of a New Drug Application for reproxalap shows promise, supported by statistically significant trial results that position it favorably for FDA approval. Despite widening net losses reported in Q3 2024, Aldeyra's strategic presentations at key healthcare conferences and its extended debt financing terms suggest a calculated approach to sustaining operations while pursuing growth. With an expected revenue surge of 55.5% annually, significantly outstripping the US market average of 9.1%, and projected earnings growth of 71.6% per year, Aldeyra is navigating its challenges with strategic initiatives that could reshape its financial landscape and bolster its market presence in upcoming years. Unlock comprehensive insights into our analysis of Aldeyra Therapeutics stock in this health report. Explore historical data to track Aldeyra Therapeutics' performance over time in our Past section. NasdaqCM:ALDX Earnings and Revenue Growth as at Dec 2024 Infinera Simply Wall St Growth Rating: \u2605\u2605\u2605\u2605\u2605\u2606 Overview: Infinera Corporation manufactures semiconductors and supplies networking equipment, optical semiconductors, software, and services globally with a market capitalization of approximately $1.56 billion. Operations: The company generates its revenue primarily from the sale of optical transport networking equipment, software, and related services, amounting to $1.46 billion. Infinera, amid a challenging fiscal period with a reported revenue decrease to $354.4 million in Q3 2024 from $392.37 million the previous year, continues to innovate in high-capacity optical networks. Despite its current unprofitability and a net loss increase to $124 million over nine months, the company is poised for recovery with strategic client engagements like Converge ICT Solutions for the Bifrost Cable System and Poka Lambro's regional network upgrade in Texas. These partnerships leverage Infinera\u2019s advanced ICE7 technology, enhancing long-distance data transmission capabilities and supporting substantial infrastructure projects. This positions Infinera uniquely within tech sectors reliant on robust data handling capacities, forecasting an annual revenue growth of 9.7%, potentially outpacing the broader US market's growth rate of 9.1%. Click to explore a detailed breakdown of our findings in Infinera's health report. Understand Infinera's track record by examining our Past report. NasdaqGS:INFN Earnings and Revenue Growth as at Dec 2024 Taking Advantage Take a closer look at our US High Growth Tech and AI Stocks list of 237 companies by clicking here. Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St , where we make it simple for investors like you to stay informed and proactive. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. Ready To Venture Into Other Investment Styles? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management . Find companies with promising cash flow potential yet trading below their fair value . This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqCM:AKBA NasdaqCM:ALDX and NasdaqGS:INFN . Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ALDX", "date": "2024-12-20T21:02:51", "sentiment": {"score": 0.02182091772556305, "confidence": 0.20996829867362976, "probabilities": {"positive": 0.20996829867362976, "negative": 0.1881473809480667, "neutral": 0.6018843650817871}}, "embedding": [-0.018231472000479698, -0.1462857574224472, -0.0481024906039238, -0.05859512835741043, -0.08964880555868149, -0.026655307039618492, 0.008583775721490383, 0.13054314255714417, 0.10623838752508163, 0.06687942892313004, -0.13240614533424377, 0.08049864321947098, -0.0186064001172781, -0.049423061311244965, -0.11314380913972855, -0.025112630799412727, 0.030961474403738976, -0.0441916398704052, -0.06492385268211365, 0.01763537898659706, 0.014098308980464935, 0.013361919671297073, 0.039820797741413116, -0.05313818156719208, 0.07484960556030273, 0.017599768936634064, -0.05153582990169525, -0.07500318437814713, -0.21769167482852936, -0.12082895636558533, 0.010815837420523167, 0.10742136836051941, 0.05500277131795883, -0.16835564374923706, -0.029848532751202583, -0.016762664541602135, -0.12690983712673187, 0.07626223564147949, 0.029982274398207664, -0.06405194103717804, 0.0915573313832283, -0.061354778707027435, -0.0822986364364624, 0.07862043380737305, -0.08688376843929291, -0.1854548454284668, -0.0753960981965065, 0.018566835671663284, 0.08006522804498672, 0.12912848591804504, -0.2147148847579956, -0.14027051627635956, 0.03163933381438255, 0.09916724264621735, -0.0602279007434845, -0.061091165989637375, -0.17857076227664948, -0.017135344445705414, 0.09367300570011139, -0.06984246522188187, 0.022874653339385986, -0.002061896026134491, 0.12278605997562408, -0.02620111033320427, 0.10363787412643433, 0.02908211573958397, -0.005991942714899778, -0.027673296630382538, -0.07778265327215195, -0.07974304258823395, 0.15119650959968567, -0.007861994206905365, -0.023428287357091904, 0.11045347154140472, -0.0925915390253067, 0.05270916223526001, 0.10940617322921753, 0.10190960764884949, 0.1698056161403656, -0.045547325164079666, 0.02166919969022274, -0.048985883593559265, -0.01429230161011219, -0.004597123246639967, -0.05027376115322113, 0.0481288880109787, 0.055060431361198425, 0.0537441149353981, 0.10170716047286987, 0.018089842051267624, 0.11783967912197113, 0.00897756777703762, -0.0009423531591892242, -0.044192805886268616, -0.05513624846935272, -0.04074148088693619, -0.10771152377128601, -0.06240478903055191, -0.03679836168885231, 0.03387896344065666, 0.0740281492471695, 0.007431593257933855, 0.0077833449468016624, -0.046396903693675995, -0.02787553332746029, -0.13990552723407745, 0.03589649498462677, -0.037208400666713715, -0.0031882538460195065, 0.06552529335021973, -0.05795818567276001, 0.014499679207801819, -0.08294253796339035, -0.0194480512291193, -0.06256146728992462, 0.04421432316303253, -0.031078936532139778, -0.054841332137584686, 0.10198590159416199, 0.036864347755908966, 0.05671115219593048, 0.061255864799022675, -0.06860130280256271, -0.03929827734827995, -0.06218000501394272, 0.07617951929569244, -0.1343863606452942, 1.4364138360233197e-32, -0.04673247039318085, 0.04067431390285492, 0.015305672772228718, 0.02737286686897278, -0.030865654349327087, -0.05445951223373413, -0.02807067707180977, -0.060593463480472565, -0.1021798774600029, -0.14975154399871826, -0.3221559524536133, 0.08380097150802612, -0.07773199677467346, 0.13992230594158173, 0.049957454204559326, -0.1078416258096695, 0.0017139138653874397, 0.04064378887414932, 0.136550173163414, -0.0178151186555624, 0.02326502464711666, 0.06041478365659714, -0.04784402996301651, 0.07341625541448593, -0.012305966578423977, 0.03966802731156349, -0.07616334408521652, 0.014141594991087914, -0.017916837707161903, 0.04140501096844673, -0.10628711432218552, 0.039986029267311096, -0.030240749940276146, -0.15771904587745667, -0.06694085150957108, -0.07671147584915161, -0.09149505943059921, -0.07039240747690201, 0.0665854811668396, 0.03008299693465233, -0.05293641239404678, 0.10294926166534424, -0.17660433053970337, 0.011569736525416374, 0.10547533631324768, 0.02854744903743267, -0.1455019861459732, 0.008762527257204056, 0.026507221162319183, -0.01715800352394581, -0.08629000186920166, 0.0347127839922905, 0.03268291801214218, -0.014215570874512196, -0.006049294024705887, 0.04757574573159218, -0.1346980780363083, -0.06916937977075577, 0.12260107696056366, 0.1056612879037857, 0.0129536222666502, 0.09095731377601624, 0.09177632629871368, 0.08170536160469055, -0.12356541305780411, 0.1582758128643036, 0.0872216448187828, 0.06960858404636383, -0.05405876040458679, 0.0950365960597992, 0.016731901094317436, -0.055403031408786774, 0.18563051521778107, 0.03792166709899902, 0.028259070590138435, -0.0043865833431482315, -0.0062044053338468075, -0.0005829594447277486, -0.03604051470756531, 0.02802843041718006, -0.0391523614525795, -0.005041351541876793, -0.0626252219080925, 0.11232683062553406, 0.07309018075466156, -0.013218829408288002, 0.002741284668445587, 0.06912154704332352, -0.1354179084300995, -0.05668123811483383, 0.009217395447194576, 0.005334924906492233, -0.12378902733325958, 0.12422654777765274, -0.02370898239314556, -1.7075016412325523e-32, 0.038281023502349854, -0.05441003292798996, 0.08116252720355988, -0.09251296520233154, -0.045327313244342804, 0.050619594752788544, 0.002223222516477108, 0.026659315451979637, 0.047233935445547104, 0.046197596937417984, 0.0481463260948658, 0.0908534824848175, -0.06414785981178284, -0.027251604944467545, -0.06539815664291382, -0.05136331543326378, 0.07050885260105133, -0.08379266411066055, 0.009403939358890057, -0.09340499341487885, 0.03716234862804413, 0.13015171885490417, -0.188596710562706, 0.12580019235610962, 0.04695146530866623, 0.0035578447859734297, -0.05218612402677536, 0.10749790072441101, -0.03200199827551842, 0.027938511222600937, -0.04230307415127754, 0.06285636126995087, -0.17995694279670715, 0.06523003429174423, -0.061954617500305176, 0.05416463315486908, 0.06838925182819366, -0.1303437352180481, 0.003851635381579399, -0.07231982052326202, 0.14729803800582886, -0.026599682867527008, 0.0037207426503300667, 0.09538666158914566, 0.051933929324150085, -0.01782720722258091, 0.05058079957962036, -0.013838216662406921, 0.11421112716197968, -0.058020055294036865, 0.047928035259246826, 0.06231136620044708, -0.021060775965452194, 0.0012491056695580482, -0.10910789668560028, 0.016547856852412224, 0.031717509031295776, 0.02071657031774521, -0.17171230912208557, -0.04759697988629341, 0.00733678974211216, 0.028560036793351173, 0.08586552739143372, -0.014034351333975792, -0.08092696964740753, 0.06073866784572601, 0.14831075072288513, 0.014586920849978924, -0.017003796994686127, -0.10738815367221832, 0.03943529725074768, -0.038672298192977905, 0.03045419417321682, -0.06503665447235107, -0.022328156977891922, 0.16288690268993378, 0.04053144529461861, -0.013519654981791973, -0.014651313424110413, 0.020094234496355057, 0.01786968857049942, -0.010281532071530819, 0.005264639854431152, 0.041086986660957336, -0.016841784119606018, 0.0836266502737999, 0.012316454201936722, -0.09688609838485718, -0.05457904562354088, 0.036557964980602264, -0.10539621114730835, -0.17857703566551208, -0.1616985946893692, -0.007104705087840557, -0.013943234458565712, -1.015753383626361e-07, 0.10892533510923386, -0.05332109332084656, 0.0213162899017334, -0.03432352468371391, 0.06241161376237869, 0.0038380715996026993, -0.08817026764154434, 0.09850317984819412, 0.060358770191669464, 0.09222851693630219, 0.04994434118270874, 0.08453721553087234, -0.17960679531097412, 0.05941754952073097, -0.03660430759191513, 0.08681170642375946, -0.11584934592247009, 0.1333010345697403, -0.032701876014471054, -0.08533713221549988, -0.05013137683272362, 0.09779556840658188, 0.09657604247331619, -0.06553755700588226, 0.10416509211063385, -0.10233168303966522, -0.07587742060422897, -0.05936865508556366, -0.009116620756685734, 0.06599409878253937, 0.06765185296535492, -0.050314247608184814, 0.07289674878120422, -0.023612186312675476, 0.08934938907623291, -0.04703562334179878, 0.0917121171951294, 0.02438621036708355, 0.03342738747596741, 0.024572834372520447, -0.07611280679702759, -0.03286949545145035, -0.00951483566313982, -0.05103391036391258, -0.006886240094900131, -0.03801194205880165, -0.12935250997543335, 0.07965166121721268, 0.10898269712924957, -0.1624782532453537, 0.06864412128925323, -0.0022208273876458406, -0.02226577326655388, -0.07459638267755508, -0.05277390033006668, 0.14752578735351562, -0.11788362264633179, -0.05354146286845207, -0.08638157695531845, 0.0018228944391012192, 0.1690390557050705, -0.19816598296165466, 0.09276750683784485, 0.11693448573350906], "changes": {"1wk": 1.2295069953377444, "1mo": -0.8196713302251629}}, {"text": "LIVE The latest news and updates on Trump's tariffs PREMIUM Aldeyra Therapeutics' Resubmitted Marketing Application for Eye Disease Drug Accepted by FDA MT Newswires Mon, Nov 18, 2024, 4:01 PM 1 min read In This Article: ALDX -1.34% ABBV +3.39% Aldeyra Therapeutics' Resubmitted Marketing Application for Eye Disease Drug Accepted by FDA PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ALDX", "date": "2024-11-18T16:01:03", "sentiment": {"score": 0.04821908287703991, "confidence": 0.060223713517189026, "probabilities": {"positive": 0.060223713517189026, "negative": 0.012004630640149117, "neutral": 0.9277716875076294}}, "embedding": [-0.00799577310681343, -0.1482556164264679, -0.008421133272349834, -0.011655651964247227, 0.16445939242839813, 0.011485563591122627, 0.1312762051820755, 0.0929967612028122, -0.1348285675048828, 0.042090971022844315, -0.018981358036398888, 0.1633240431547165, 0.06155313551425934, 0.009266012348234653, -0.0506606362760067, 0.14841410517692566, 0.10080013424158096, -0.17168137431144714, -0.17327798902988434, 0.14198900759220123, 0.022847825661301613, 0.013335708528757095, 0.1571662724018097, 0.0868881568312645, -0.02784098871052265, 0.02414531446993351, -0.16160064935684204, -0.10701701045036316, -0.011780277825891972, -0.06899607181549072, -0.030920878052711487, 0.0684112012386322, -0.058352965861558914, -0.12230434268712997, -0.03248902037739754, -0.18560601770877838, -0.15505962073802948, -0.05928020179271698, -0.1270255148410797, 0.06536423414945602, 0.17901213467121124, -0.24360960721969604, -0.2390168458223343, 0.2667265236377716, -0.06415772438049316, -0.17613385617733002, -0.045801792293787, 0.19622007012367249, 0.0839822068810463, 0.21961112320423126, -0.13594914972782135, -0.21390555799007416, 0.03606901317834854, -0.01556337345391512, 0.0644356980919838, -0.10998637229204178, -0.2383761703968048, -0.09858135133981705, 0.05512561649084091, -0.04146719351410866, 0.025141023099422455, 0.015318800695240498, -0.023957230150699615, 0.15748025476932526, -0.12234817445278168, 0.07000464200973511, -0.08488361537456512, -0.08170726895332336, -0.025253264233469963, -0.143756702542305, -0.01461960468441248, -0.07068424671888351, 0.05022735148668289, 0.06953085958957672, 0.05285860225558281, 0.03518695384263992, 0.2720129191875458, -0.12759903073310852, 0.08444792777299881, -0.0272823553532362, 0.08386926352977753, 0.034039516001939774, 0.15022729337215424, -0.014275074005126953, 0.09791531413793564, -0.15170788764953613, -0.010964291170239449, -0.00949994008988142, 0.020530780777335167, -0.11820882558822632, 0.18202857673168182, -0.0529245100915432, -0.01858201064169407, -0.02624753676354885, -0.16807442903518677, 0.05114090442657471, -0.03995096683502197, 0.01564362645149231, -0.20285320281982422, 0.07369058579206467, -0.03515581041574478, -0.16210953891277313, -0.1151747927069664, -0.06250574439764023, -0.16083167493343353, -0.14858312904834747, 0.013746015727519989, 0.16144172847270966, -0.05265814810991287, 0.13271896541118622, -0.048050470650196075, 0.019267216324806213, 0.07340019196271896, -0.09851673990488052, -0.11771362274885178, 0.13016125559806824, -0.10295766592025757, -0.2560771405696869, 0.17479029297828674, -0.06752029806375504, 0.10010422021150589, 0.1272464245557785, 0.07762512564659119, 0.02314620278775692, 0.0423210933804512, -0.0151082007214427, -0.08467467129230499, 1.0416654944755209e-32, -0.18779528141021729, 0.07523756474256516, -0.027944453060626984, -0.060610491782426834, 0.0755840390920639, -0.020017944276332855, -0.04852386191487312, -0.03503817319869995, -0.17124533653259277, -0.15212534368038177, -0.1912093460559845, 0.17620126903057098, 0.008876997977495193, 0.2801022529602051, -0.14086848497390747, -0.11552336066961288, -0.01732524484395981, 0.13494360446929932, 0.12052668631076813, 0.028886379674077034, 0.08478447049856186, -0.04829694703221321, -0.06137543171644211, 0.11857536435127258, -0.0853397324681282, 0.2251432240009308, 0.030085783451795578, 0.01844196207821369, 0.13964135944843292, 0.07973646372556686, -0.070148766040802, 0.12372139096260071, 0.0071051232516765594, -0.1693241149187088, -0.01834423653781414, 0.11404786258935928, -0.1081729382276535, -0.09116850793361664, -0.12712673842906952, -0.041969165205955505, -0.02035011164844036, 0.2149430364370346, -0.05559443682432175, 0.1251194179058075, 0.11593353003263474, 0.06776148825883865, -0.11499112099409103, 0.0729038193821907, 0.07900343835353851, -0.20452924072742462, 0.029331639409065247, 0.05123661085963249, -0.0879848301410675, -0.11414079368114471, -0.09683383256196976, 0.09058316797018051, -0.19670547544956207, -0.12643004953861237, 0.040429338812828064, -0.07243014872074127, 0.13248011469841003, 0.0024951479863375425, 0.03540000319480896, 0.05413326248526573, -0.2011774480342865, 0.017290983349084854, -0.06330496072769165, -0.16480796039104462, -0.27153125405311584, -0.030059032142162323, 0.05555817857384682, 0.07835014909505844, 0.04901137948036194, 0.027845002710819244, -0.13693919777870178, 0.0053010801784694195, 0.01690979115664959, 0.014613769017159939, 0.15280278027057648, -0.0799860954284668, 0.007304009050130844, -0.09930864721536636, 0.21495303511619568, 0.041874971240758896, -0.008152639493346214, -0.05288007855415344, -0.07145027071237564, 0.02051675133407116, -0.09503882378339767, 0.04488397017121315, 0.0195523239672184, 0.10815439373254776, -0.1166006401181221, -0.0028191779274493456, 0.0541531965136528, -1.6475883104758727e-32, -0.1690509021282196, 0.0399036668241024, 0.10467852652072906, -0.17503125965595245, 0.024589035660028458, 0.15139777958393097, 0.045837629586458206, 0.14814722537994385, 0.3890847861766815, 0.06613016873598099, 0.10310439765453339, 0.06765294820070267, -0.142115518450737, 0.030716167762875557, -0.06299407035112381, -0.04298530891537666, 0.130841925740242, -0.04748624563217163, -0.09981068968772888, 0.022327091544866562, -0.03592059761285782, 0.21187984943389893, -0.1732565313577652, 0.07721719890832901, -0.020000295713543892, -0.09231061488389969, 0.16531290113925934, 0.02765536867082119, 0.034480929374694824, -0.045119062066078186, -0.14033794403076172, 0.03080684505403042, -0.23463907837867737, 0.0396258644759655, -0.13149729371070862, 0.0878886878490448, 0.09624523669481277, -0.06582704931497574, -0.09785180538892746, -0.018130477517843246, 0.1947275549173355, -0.12879721820354462, -0.1338358074426651, 0.01864357851445675, 0.12086201459169388, 0.08341299742460251, -0.10501512885093689, 0.01930878311395645, 0.11982938647270203, -0.12441043555736542, -0.06868499517440796, 0.0022676491644233465, 0.08414572477340698, 0.07841979712247849, -0.15454301238059998, 0.12510347366333008, 0.09028531610965729, 0.002763136522844434, 0.11269374936819077, 0.011524595320224762, 0.02274332009255886, 0.1893717646598816, -0.06716269254684448, -0.24082955718040466, 0.03344352915883064, -0.013261957094073296, 0.08965521305799484, -0.11442606896162033, 0.11923424899578094, -0.09766104817390442, 0.14963845908641815, -0.10123667865991592, -0.32679757475852966, -0.06999228149652481, 0.008611656725406647, 0.12430348247289658, 0.010166255757212639, 0.03579884022474289, -0.18046702444553375, 0.07545159012079239, 0.18319812417030334, -0.022474585101008415, 0.0846857875585556, 0.026016347110271454, 0.03049391694366932, 0.009350297972559929, 0.2309425324201584, -0.09286510944366455, -0.17110073566436768, 0.05511168763041496, -0.2868120074272156, -0.217037633061409, -0.26058077812194824, 0.08117568492889404, -0.01584741100668907, -1.0106153780498062e-07, 0.07651659846305847, 0.026595856994390488, -0.016002735123038292, 0.07468748837709427, 0.014168310910463333, 0.12323318421840668, -0.1638386845588684, 0.03579188510775566, -0.07423181086778641, 0.09861215949058533, -0.03093068301677704, 0.1857062727212906, -0.12190387398004532, 0.06824297457933426, 0.02784973755478859, 0.026366865262389183, 0.049687571823596954, 0.0541771836578846, -0.07011581212282181, -0.09848925471305847, -0.10960336774587631, 0.2369985431432724, 0.07752163708209991, -0.05799322575330734, 0.07964988052845001, 0.001173345954157412, -0.049313489347696304, 0.061149902641773224, 0.03818392753601074, 0.02997298166155815, -0.030678212642669678, 0.03890495374798775, -0.038809750229120255, -0.0713067352771759, -0.0752890408039093, -0.07948192209005356, 0.03623056784272194, 0.07848310470581055, 0.2309385985136032, 0.03345806151628494, 0.0012035826221108437, -0.040590688586235046, 0.15774185955524445, 0.012922882102429867, -0.03251698613166809, 0.0294139813631773, -0.15156781673431396, -0.18171468377113342, 0.2058187872171402, 0.05728606879711151, 0.15553542971611023, -0.19730761647224426, 0.07386410236358643, -0.18153533339500427, -0.08881860971450806, -0.07673872262239456, -0.01694650761783123, -0.1931087225675583, -0.086079902946949, -0.07380235195159912, 0.2357729822397232, -0.19171255826950073, 0.13985668122768402, 0.1886877566576004], "changes": {"1wk": 3.1914915203131624, "1mo": 13.404258298032165}}, {"text": "LIVE The latest news and updates on Trump's tariffs Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference Business Wire Mon, Dec 2, 2024, 3:00 PM 1 min read In This Article: ALDX -1.34% LEXINGTON, Mass., December 02, 2024 --( BUSINESS WIRE )-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in the Eyes Wide Open on Ophthalmology Panel at the Citi 2024 Global Healthcare Conference. The conference is being conducted in Miami, Florida December 2-5, 2024. Dr. Brady\u2019s participation in the Eyes Wide Open on Ophthalmology Panel is scheduled to begin at 1:45 p.m. ET on Thursday, December 5, 2024. To view the live webcast, log in to the Investors & Media section of the Aldeyra website at https://ir.aldeyra.com . Following the fireside chat, the webcast will be archived for 90 days. About Aldeyra Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-248, ADX-743, ADX-631, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. View source version on businesswire.com: https://www.businesswire.com/news/home/20241202913411/en/ Contacts Investor & Media Contact: Laura Nichols Tel: (781) 257-3060 investorrelations@aldeyra.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ALDX", "date": "2024-12-02T15:00:00", "sentiment": {"score": 0.07381837069988251, "confidence": 0.08405964821577072, "probabilities": {"positive": 0.08405964821577072, "negative": 0.010241277515888214, "neutral": 0.9056990146636963}}, "embedding": [-0.077262744307518, -0.16718722879886627, -0.03909087926149368, 0.023142866790294647, 0.009527742862701416, 0.005712669808417559, 0.007954802364110947, 0.1249663457274437, 0.024599596858024597, 0.14047370851039886, -0.1452014446258545, 0.009910935536026955, 0.057243674993515015, 0.11450405418872833, -0.1053527295589447, 0.2228924185037613, 0.010082812048494816, 0.023591607809066772, -0.10716811567544937, 0.08872932195663452, 0.07981157302856445, 0.02781130000948906, -0.015855200588703156, -0.007290607318282127, -0.0717681497335434, -0.0027073584496974945, -0.07744239270687103, -0.04625947028398514, -0.2011014074087143, -0.11329933255910873, 0.03144872561097145, 0.12317630648612976, -0.12444570660591125, -0.09444394707679749, -0.044054292142391205, 0.057481225579977036, -0.1508089303970337, -0.05057065561413765, -0.15901662409305573, 0.0013423450291156769, -0.03592350706458092, 0.02611236646771431, -0.17126767337322235, 0.09175661951303482, 0.03386359661817551, -0.1946040391921997, 0.009623277932405472, 0.12526734173297882, 0.10558164119720459, 0.12369862198829651, -0.18156138062477112, -0.08834558725357056, -0.053319744765758514, 0.12990009784698486, 0.07674242556095123, 0.03706473484635353, -0.19834774732589722, -0.005052827298641205, 0.09543179720640182, -0.056539975106716156, 0.09766685962677002, -0.09601478278636932, 0.008577398955821991, 0.040716394782066345, -0.037761516869068146, -0.050261661410331726, 0.003080090507864952, -0.08931531012058258, 0.04005737602710724, -0.1263388693332672, -0.1017056405544281, -0.060605935752391815, 0.07574070990085602, 0.06907673180103302, 0.024773478507995605, 0.08395601809024811, 0.14880980551242828, -0.05374413728713989, 0.1140098050236702, -0.014506387524306774, 0.20766031742095947, 0.1480235457420349, 0.18728047609329224, 0.0745253786444664, 0.10897098481655121, -0.031015850603580475, 0.020103147253394127, 0.05709134042263031, 0.11157554388046265, -0.07099074870347977, -0.011604854837059975, 0.03183098882436752, -0.05759438872337341, -0.03636693209409714, -0.06600259989500046, -0.031414568424224854, 0.014871504157781601, 0.023235764354467392, -0.06720656156539917, 0.048667531460523605, -0.0496649444103241, -0.04818347468972206, -0.04446864873170853, -0.07591108977794647, -0.08383454382419586, -0.029550207778811455, 0.061410583555698395, 0.11647912859916687, -0.05233406275510788, 0.03830599784851074, -0.03921224921941757, 0.08784109354019165, 0.009344939142465591, -0.08809202909469604, 0.017131157219409943, 0.1655396670103073, -0.022951586171984673, -0.18256014585494995, 0.16641254723072052, -0.07334404438734055, 0.05583877116441727, -0.02075648307800293, 0.09927752614021301, -0.07217851281166077, 0.17970456182956696, 0.07732799649238586, -0.04407210648059845, 5.0033333798796904e-33, 0.02708759717643261, 0.0391717404127121, -0.04770294576883316, 0.08391658961772919, 0.1725718379020691, -0.04232872277498245, 0.02423817664384842, 0.059964343905448914, -0.16899994015693665, -0.10242672264575958, -0.08875906467437744, 0.028201159089803696, 0.05791760981082916, 0.19602355360984802, 0.010858800262212753, -0.10812241584062576, 0.06309135258197784, 0.02825978957116604, 0.01914241537451744, -0.1310761272907257, -0.12216036021709442, 0.044061142951250076, -0.10600826144218445, 0.10011397302150726, -0.0010400388855487108, 0.14670011401176453, 0.01697569526731968, 0.06896335631608963, 0.07897184789180756, 0.026017317548394203, -0.14159613847732544, 0.12597359716892242, -0.047904931008815765, -0.08484937250614166, -0.03233892843127251, -0.005675852298736572, -0.06836959719657898, -0.1595945954322815, 0.04977858066558838, -0.00803470704704523, 0.004908856004476547, 0.1376543492078781, -0.07047440111637115, -0.059111982583999634, 0.12277065217494965, -0.005768682807683945, -0.13353972136974335, 0.22323769330978394, 0.008849512785673141, -0.028156239539384842, 0.10091254115104675, -0.042136095464229584, 0.06626036763191223, -0.15850692987442017, -0.12766584753990173, 0.030869854614138603, -0.3059758245944977, -0.05818260461091995, 0.0955275446176529, 0.16148421168327332, -0.09652208536863327, -0.05727207288146019, -0.1355440467596054, 0.15174520015716553, -0.06715305149555206, 0.017306014895439148, -0.008049390278756618, -0.10869279503822327, -0.03145892173051834, 0.01915351301431656, -0.07061411440372467, 0.00913285929709673, 0.23408006131649017, -0.03232850879430771, 0.07763361930847168, -0.020741598680615425, 0.15345701575279236, 0.059674330055713654, 0.04173722118139267, -0.005155947990715504, 0.014756887219846249, 0.11013349890708923, -0.034198351204395294, 0.07770863175392151, -0.07494518160820007, -0.2053259164094925, 0.021446499973535538, -0.0013087624683976173, -0.1277538686990738, -0.07058784365653992, 0.09553856402635574, -0.00023476779460906982, -0.05121748894453049, 0.056922975927591324, 0.028465144336223602, -6.045914217112517e-33, 0.039748843759298325, -0.09893117845058441, 0.017050476744771004, -0.13673833012580872, 0.03297416865825653, 0.16905009746551514, 0.13745266199111938, -0.02361082285642624, 0.1493958830833435, -0.21983495354652405, 0.1527182161808014, -0.03143179789185524, -0.07679694890975952, -0.03152967244386673, -0.17495742440223694, -0.0517752468585968, -0.025595298036932945, -0.07880672812461853, -0.1319541484117508, 0.08887991309165955, -4.508253186941147e-05, 0.20752392709255219, -0.07927097380161285, -0.07241426408290863, 0.0445265918970108, 0.0605781152844429, 0.06211322173476219, 0.07934209704399109, 0.06639339029788971, 0.09132666885852814, -0.09115587174892426, 0.04021309316158295, -0.26946011185646057, -0.01324186846613884, 0.017131352797150612, 0.16101667284965515, -0.02050940878689289, -0.13743193447589874, -0.08177778124809265, -0.0344165600836277, 0.22834351658821106, -0.05402403697371483, -0.10850305110216141, 0.010914219543337822, 0.17090070247650146, 0.0869276225566864, -0.08949117362499237, -0.025009404867887497, 0.04100373387336731, -0.13624447584152222, -0.030680818483233452, -0.06429431587457657, -0.036155831068754196, 0.025128142908215523, -0.04581265524029732, 0.0287841334939003, 0.08180759847164154, -0.056611377745866776, 0.09346423298120499, 0.011873493902385235, -0.03872302919626236, -0.01615811511874199, 0.08639667928218842, -0.07711996138095856, 0.056291572749614716, 0.11629636585712433, 0.0789741575717926, -0.026391351595520973, 0.10985397547483444, -0.08622194826602936, 0.061676569283008575, -0.014194993302226067, -0.04613036662340164, -0.028379902243614197, -0.0022878283634781837, 0.06248348206281662, -0.03180508688092232, -0.04619865119457245, -0.2209070324897766, 0.1324876844882965, 0.08704856783151627, -0.020554890856146812, -0.010077815502882004, 0.046730224043130875, 0.06971381604671478, 0.15177303552627563, 0.07886376976966858, 0.062218792736530304, -0.012849733233451843, 0.06303626298904419, -0.17067551612854004, -0.15513324737548828, -0.1590590626001358, 0.1547626256942749, 0.04604727029800415, -1.002803600158586e-07, 0.13407021760940552, 0.0813525840640068, 0.03898770362138748, -0.173217311501503, -0.02205231785774231, 0.06462787091732025, -0.06559474021196365, 0.046555716544389725, -0.01186305284500122, 0.13616034388542175, 0.05090474709868431, 0.2407638281583786, -0.0273019727319479, 0.09747061133384705, -0.017403675243258476, 0.0761270746588707, -0.06222992017865181, -0.06900382786989212, -0.09078594297170639, -0.05314622074365616, -0.15148116648197174, 0.05144808813929558, -0.031480323523283005, 0.0007398985326290131, 0.0824500322341919, -0.15364739298820496, -0.05527965724468231, 0.020231597125530243, -0.03182576596736908, 0.0017648616340011358, 0.0027615863364189863, 0.0262225940823555, 0.09538788348436356, -0.018006086349487305, -0.09046860039234161, -0.15006421506404877, 0.07975073903799057, 0.05339548736810684, 0.03872746229171753, 0.1106691062450409, -0.010756365954875946, 0.03256481885910034, 0.045061685144901276, -0.019583571702241898, -0.04623796418309212, -0.12970246374607086, -0.004590840078890324, -0.053566060960292816, 0.01410115510225296, 0.0027970727533102036, -0.005481346044689417, -0.06863607466220856, -0.06262156367301941, -0.16029372811317444, -0.11454389989376068, -0.04223831743001938, -0.05281269922852516, -0.10874012112617493, -0.046483829617500305, -0.11851678788661957, -0.00818369910120964, -0.02910345420241356, 0.09178714454174042, 0.057771921157836914], "changes": {"1wk": 8.29874697685747, "1mo": 3.5269625187210516}}, {"text": "LIVE The latest news and updates on Trump's tariffs Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement Business Wire Mon, Nov 18, 2024, 3:00 PM 7 min read In This Article: ALDX -1.34% PDUFA Date is April 2, 2025 LEXINGTON, Mass., November 18, 2024 --( BUSINESS WIRE )-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for topical ocular reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease. The FDA assigned a Prescription Drug User Fee Act (PDUFA) date of April 2, 2025. In conjunction with the acceptance of the NDA for review, Aldeyra announced the expansion of its exclusive option agreement with AbbVie Inc. (AbbVie). \"Based on the FDA\u2019s acceptance of the NDA resubmission of reproxalap for dry eye disease for review, we are pleased to announce an expansion of our option agreement with AbbVie, highlighting the commitment of both companies to accelerating the potential availability of a novel dry eye disease therapy to patients and physicians,\" stated Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra. On October 31, 2023, Aldeyra entered into an option agreement with AbbVie. Under the terms of the agreement, AbbVie has the option to obtain a co-exclusive license to develop, manufacture, and commercialize reproxalap in the United States. Upon exercise of the option, AbbVie would pay Aldeyra a $100 million upfront cash payment, less previously paid option fees of $6 million. In addition, Aldeyra would be eligible to receive up to $300 million in regulatory and commercial milestone payments, inclusive of a $100 million milestone payment payable if the FDA approval for reproxalap for dry eye disease is received. In the United States, Aldeyra would share profits and losses with AbbVie from the commercialization of reproxalap according to a split of 60% for AbbVie and 40% for Aldeyra. Per the expansion of the option agreement, Aldeyra will initiate certain pre-commercial activities, 60% of which will be paid by AbbVie and 40% of which will be paid by Aldeyra if the option is exercised. AbbVie has also independently initiated certain pre-commercial planning activities. The parties have also agreed to amend the expiration of the option to 10 business days from the date of FDA approval, if any, of reproxalap for dry eye disease. About Reproxalap Reproxalap is an investigational new drug candidate in development for the treatment of dry eye disease and allergic conjunctivitis, two of the largest markets in ophthalmology. Reproxalap is a first-in-class small-molecule modulator of RASP, which are elevated in ocular and systemic inflammatory diseases. The mechanism of action of reproxalap has been supported by the demonstration of statistically significant and clinically relevant activity in multiple physiologically distinct late-phase clinical indications. Reproxalap has been studied in more than 2,500 patients with no observed safety concerns; mild and transient instillation site irritation is the most commonly reported adverse event in clinical trials. Story Continues About Aldeyra Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Aldeyra\u2019s approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Aldeyra\u2019s product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-248, ADX-743, ADX-631, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Aldeyra\u2019s late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. For additional information, please visit www.aldeyra.com . Safe Harbor Statement This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Aldeyra\u2019s future expectations, plans, and prospects, including without limitation statements regarding: the goals, opportunity, and potential for reproxalap; the outcome and timing of the FDA\u2019s review, or approval of the resubmitted NDA for reproxalap by the PDUFA date and the adequacy of the data included in the original NDA and the resubmitted NDA; the likelihood and timing of the exercise of the Option; and Aldeyra\u2019s expectations regarding the labeling for reproxalap, if approved. Aldeyra intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as, but not limited to, \"may,\" \"might,\" \"will,\" \"objective,\" \"intend,\" \"should,\" \"could,\" \"can,\" \"would,\" \"expect,\" \"believe,\" \"anticipate,\" \"project,\" \"on track,\" \"scheduled,\" \"target,\" \"design,\" \"estimate,\" \"predict,\" \"contemplates,\" \"likely,\" \"potential,\" \"continue,\" \"ongoing,\" \"aim,\" \"plan,\" or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue. All of Aldeyra's development timelines may be subject to adjustment depending on recruitment rate, regulatory review, preclinical and clinical results, funding, and other factors that could delay the initiation, enrollment, or completion of clinical trials. Important factors that could cause actual results to differ materially from those reflected in Aldeyra's forward-looking statements include, among others, the timing of enrollment, commencement and completion of Aldeyra's clinical trials, the timing and success of preclinical studies and clinical trials conducted by Aldeyra and its development partners; delay in or failure to obtain regulatory approval of Aldeyra's product candidates, including as a result of the FDA not accepting Aldeyra\u2019s regulatory filings, issuing a complete response letter, or requiring additional clinical trials or data prior to review or approval of such filings or in connection with resubmissions of such filings; the ability to maintain regulatory approval of Aldeyra's product candidates, and the labeling for any approved products; the risk that prior results, such as signals of safety, activity, or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Aldeyra's product candidates in clinical trials focused on the same or different indications; the scope, progress, expansion, and costs of developing and commercializing Aldeyra's product candidates; uncertainty as to Aldeyra\u2019s ability to commercialize (alone or with others) and obtain reimbursement for Aldeyra's product candidates following regulatory approval, if any; the size and growth of the potential markets and pricing for Aldeyra's product candidates and the ability to serve those markets; Aldeyra's expectations regarding Aldeyra's expenses and future revenue, the timing of future revenue, the sufficiency or use of Aldeyra's cash resources and needs for additional financing; the rate and degree of market acceptance of any of Aldeyra's product candidates; Aldeyra's expectations regarding competition; Aldeyra's anticipated growth strategies; Aldeyra's ability to attract or retain key personnel; Aldeyra\u2019s commercialization, marketing and manufacturing capabilities and strategy; Aldeyra's ability to establish and maintain development partnerships; Aldeyra\u2019s ability to successfully integrate acquisitions into its business; Aldeyra's expectations regarding federal, state, and foreign regulatory requirements; political, economic, legal, social, and health risks, public health measures, and war or other military actions, that may affect Aldeyra\u2019s business or the global economy; regulatory developments in the United States and foreign countries; Aldeyra's ability to obtain and maintain intellectual property protection for its product candidates; the anticipated trends and challenges in Aldeyra's business and the market in which it operates; and other factors that are described in the \"Risk Factors\" and \"Management's Discussion and Analysis of Financial Condition and Results of Operations\" sections of Aldeyra's Annual Report on Form 10-K for the year ended December 31, 2023, and Aldeyra\u2019s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC's website at https://www.sec.gov/ . In addition to the risks described above and in Aldeyra's other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra's results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20241118246408/en/ Contacts Investor & Media Contact: Laura Nichols Tel: (781) 257-3060 investorrelations@aldeyra.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ALDX", "date": "2024-11-18T15:00:00", "sentiment": {"score": 0.7691800612956285, "confidence": 0.7776423096656799, "probabilities": {"positive": 0.7776423096656799, "negative": 0.008462248370051384, "neutral": 0.21389548480510712}}, "embedding": [-0.10404184460639954, -0.12161881476640701, 0.02997991070151329, -0.07350447028875351, -0.046965885907411575, -0.0087751979008317, 0.027644500136375427, 0.14622002840042114, 0.019040312618017197, 0.06873545795679092, -0.044715411961078644, 0.09505899250507355, 0.005155778490006924, 0.03624117374420166, -0.0430946908891201, 0.11307492852210999, 0.12079864740371704, -0.11944256722927094, -0.11474110186100006, 0.18571878969669342, 0.15116125345230103, 0.014304755255579948, 0.05487927049398422, 0.013026909902691841, -0.04468218982219696, 0.049028731882572174, -0.06768716871738434, -0.10270993411540985, -0.16409283876419067, -0.1380765736103058, 0.07471412420272827, 0.17381978034973145, -0.03695112466812134, -0.2023218870162964, 0.004046635702252388, -0.09607294201850891, -0.11797807365655899, -0.061339735984802246, -0.14902225136756897, 0.11021751910448074, 0.00027375156059861183, -0.06046780198812485, -0.22690322995185852, 0.20493806898593903, 0.037115201354026794, -0.22405372560024261, -0.0017688833177089691, 0.19361136853694916, 0.077451191842556, 0.24062007665634155, -0.0677376464009285, -0.12160472571849823, 0.014557922258973122, 0.038775887340307236, -0.0508035309612751, 0.001967645948752761, -0.16113582253456116, -0.06750640273094177, 0.04741214960813522, 0.0552089586853981, -0.012030537240207195, -0.018393997102975845, -0.013732194900512695, 0.07039661705493927, 0.03834659606218338, 0.05619378387928009, 0.03837631270289421, -0.20572328567504883, -0.021918606013059616, -0.09506415575742722, -0.027089029550552368, -0.06962324678897858, 0.10808394849300385, 0.08419336378574371, -0.04199283570051193, 0.08138027787208557, 0.18416224420070648, 0.010129809379577637, 0.12284596264362335, -0.09210006892681122, 0.12678220868110657, 0.07631134986877441, 0.060906782746315, -0.03226107358932495, 0.0215180441737175, -0.05035434663295746, -0.01794881373643875, 0.08657046407461166, 0.08198539167642593, -0.06702668964862823, 0.10975055396556854, -0.04717626795172691, -0.05622664466500282, -0.05760430917143822, -0.013735685497522354, 0.038897693157196045, -0.06612089276313782, -0.02777281031012535, -0.005395516753196716, 0.047287605702877045, -0.011676615104079247, -0.09375938028097153, -0.1021043062210083, -0.09732163697481155, -0.055104538798332214, -0.08758196234703064, 0.07521764189004898, -0.05351445823907852, 0.034709639847278595, 0.07936827093362808, -0.12051808834075928, 0.03067486733198166, 0.05416952073574066, 0.01913198083639145, -0.102403424680233, 0.1838264912366867, -0.06467366218566895, -0.12504082918167114, 0.2084536850452423, -0.11748367547988892, 0.09467460215091705, 0.03727148473262787, 0.050852566957473755, -0.10148539394140244, 0.08012092113494873, 0.016620757058262825, -0.03279692679643631, 8.687091331672836e-33, -0.09194052219390869, 0.0069879284128546715, -0.026702450588345528, -0.046127475798130035, -0.0009160265326499939, 0.02242281101644039, 0.030394207686185837, 0.13328930735588074, -0.20765459537506104, -0.12006048858165741, -0.19603709876537323, 0.04495270550251007, -0.012981611303985119, 0.1673719584941864, -0.1023964136838913, -0.09106558561325073, 0.010329661890864372, 0.1370222419500351, 0.09410883486270905, 0.04926268011331558, -0.06771501153707504, 0.04176683723926544, -0.05471009761095047, 0.12152384221553802, -0.13956251740455627, 0.162028968334198, -0.04693913459777832, 0.05920788273215294, 0.10621695965528488, 0.014638818800449371, -0.03134710341691971, 0.0654284730553627, 0.08513647317886353, -0.08819468319416046, -0.07296101748943329, -0.04624912515282631, -0.09177669882774353, -0.11030372977256775, -0.04515030235052109, -0.04730602353811264, -0.01311444491147995, 0.2187148928642273, -0.09762103855609894, -0.01658039167523384, 0.04512973129749298, -0.010582854971289635, -0.08207282423973083, 0.0792035460472107, -0.029868360608816147, -0.06973901391029358, 0.03815574198961258, 0.10146212577819824, -0.07436846196651459, -0.16384704411029816, -0.08306494355201721, 0.03611905127763748, -0.18370208144187927, -0.09925153851509094, 0.1048731654882431, 0.10070540010929108, 0.04331088438630104, 0.14453673362731934, 0.021304644644260406, 0.04530277103185654, -0.23347872495651245, 0.042773641645908356, 0.03601953387260437, -0.04860552400350571, -0.0441928431391716, -0.09285394847393036, -0.03673909232020378, 0.016882602125406265, 0.1680949181318283, -0.0006890390068292618, 0.073621965944767, -0.06322629004716873, 0.1483968049287796, 0.03859568014740944, 0.11942523717880249, -0.08867235481739044, -0.012777859345078468, -0.005526069551706314, 0.09002988040447235, 0.08863133192062378, 0.020545005798339844, -0.04634764790534973, -0.06045401096343994, 0.078749880194664, -0.12798158824443817, -0.10957212746143341, 0.057373277842998505, 0.007220604922622442, -0.03296177089214325, 0.03746119886636734, 0.27789923548698425, -1.1117838059704673e-32, -0.007282825652509928, -0.03781389817595482, 0.012257527559995651, -0.11612381041049957, 0.054756227880716324, 0.11651970446109772, 0.07161690294742584, 0.027785686776041985, 0.17449064552783966, -0.09177014231681824, 0.027020905166864395, 0.030571168288588524, -0.07346098870038986, -0.04950225353240967, -0.045835837721824646, 0.015705790370702744, -0.08664528280496597, -0.10188208520412445, -0.06171170249581337, 0.066617950797081, 0.05549890175461769, 0.18739037215709686, -0.07472264766693115, 0.028920937329530716, 0.03055116906762123, 0.024289272725582123, 0.14690440893173218, 0.011570857837796211, 0.05682248994708061, 0.013953202404081821, -0.07337254285812378, -0.012899636290967464, -0.38069653511047363, 0.04205670207738876, -0.03653953969478607, -0.0007614884525537491, 0.02497873827815056, -0.14463108777999878, -0.12121862918138504, -0.06591323763132095, 0.17165344953536987, -0.05816105008125305, -0.07260329276323318, -0.026319682598114014, 0.09069275856018066, 0.0258133877068758, -0.016010023653507233, -0.13412980735301971, 0.11010125279426575, -0.014529943466186523, -0.07937460392713547, 0.014844479039311409, 0.02788909524679184, -0.001056319335475564, -0.08664931356906891, 0.07799246162176132, 0.11092483997344971, -0.013838562183082104, 0.09576527774333954, 0.08322571218013763, 0.0443282350897789, 0.11730842292308807, 0.060658060014247894, -0.11555936187505722, 0.09205381572246552, 0.0793531984090805, 0.1094639003276825, 0.026596881449222565, 0.1105152815580368, -0.034900035709142685, -0.009926920756697655, -0.087143674492836, -0.18043848872184753, -0.0650261864066124, 0.05892889201641083, 0.14864079654216766, -0.013125453144311905, -0.1437569409608841, -0.21753822267055511, 0.028798477724194527, 0.01601812243461609, -0.07608678936958313, 0.03940668702125549, 0.11943334341049194, 0.05081697925925255, 0.031998131424188614, 0.09556004405021667, -0.08863753080368042, -0.04022350534796715, 0.15655453503131866, -0.14176324009895325, -0.1737869679927826, -0.12780460715293884, 0.07746776193380356, 0.006613872479647398, -1.0081433998720968e-07, 0.05438743531703949, 0.019262906163930893, 0.04642447084188461, -0.0028060676995664835, 0.09330493211746216, -0.048202577978372574, -0.13541042804718018, 0.10922877490520477, 0.02522324025630951, 0.03161359950900078, 0.05767837539315224, 0.20498810708522797, -0.08750829100608826, 0.08164981007575989, -0.012114861980080605, 0.09295934438705444, -0.008269228041172028, -0.005538370460271835, -0.08955015242099762, -0.015353965573012829, -0.2107919156551361, 0.06731013208627701, -0.03418077528476715, -0.0062782736495137215, 0.054705895483493805, -0.10054048895835876, 0.016351735219359398, 0.15491828322410583, -0.019023755565285683, 0.08859656751155853, 0.006671138573437929, 0.024595333263278008, -0.04351286590099335, -0.055365074425935745, -0.05187200754880905, -0.2589002251625061, 0.04532402753829956, 0.12251709401607513, 0.12920817732810974, 0.08334226906299591, -0.05282217264175415, 0.012516596354544163, 0.03626547008752823, -0.0014491621404886246, 0.030228395015001297, -0.09194818139076233, -0.1319069117307663, -0.1675965040922165, 0.057486727833747864, -0.027807926759123802, 0.07328431308269501, -0.09361638128757477, -0.03596949204802513, -0.10479725897312164, -0.009733445942401886, -0.02175726741552353, -0.058266982436180115, -0.10824979096651077, -0.04751439765095711, -0.08616965264081955, 0.031633395701646805, -0.16243943572044373, 0.16698700189590454, 0.08108814805746078], "changes": {"1wk": 3.1914915203131624, "1mo": 13.404258298032165}}, {"text": "LIVE The latest news and updates on Trump's tariffs Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference Business Wire Thu, Nov 14, 2024, 3:00 PM 1 min read In This Article: ALDX -1.34% LEXINGTON, Mass., November 14, 2024 --( BUSINESS WIRE )-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference 2024. The conference is being conducted in London, England November 19- 21, 2024. Dr. Brady\u2019s conversation with Kelly Shi, Ph.D., Senior Vice President, Biotechnology Equity Research at Jefferies LLC., is scheduled to begin at 12:30 p.m. GMT Thursday, November 21, 2024. To view the live webcast, log in to the Investors & Media section of the Aldeyra website at https://ir.aldeyra.com . Following the fireside chat, the webcast will be archived for 90 days. About Aldeyra Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-248, ADX-743, ADX-631, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. View source version on businesswire.com: https://www.businesswire.com/news/home/20241114786147/en/ Contacts Investor & Media Contact: Laura Nichols Tel: (781) 257-3060 investorrelations@aldeyra.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ALDX", "date": "2024-11-14T15:00:00", "sentiment": {"score": 0.06418247893452644, "confidence": 0.07503002882003784, "probabilities": {"positive": 0.07503002882003784, "negative": 0.010847549885511398, "neutral": 0.9141224026679993}}, "embedding": [-0.07541295886039734, -0.1434791088104248, -0.0360419936478138, 0.020648760721087456, -0.008477341383695602, 0.015662124380469322, 0.021180929616093636, 0.1030483990907669, 0.01889597810804844, 0.08224130421876907, -0.1838184893131256, 0.03816234692931175, 0.04205324873328209, 0.06993971765041351, -0.08999080955982208, 0.17083734273910522, 0.03921595588326454, 0.029033593833446503, -0.106549933552742, 0.09156101197004318, 0.057813555002212524, 0.0530211515724659, 0.0023743361234664917, 0.026059336960315704, -0.06638795137405396, -0.021617520600557327, -0.0769851803779602, -0.011362623423337936, -0.20579871535301208, -0.10067640244960785, 0.08588516712188721, 0.13989834487438202, -0.09759613871574402, -0.09602873772382736, -0.048461806029081345, 0.06756121665239334, -0.12657466530799866, -0.04486031085252762, -0.12417793273925781, -0.022400906309485435, -0.019933415576815605, -0.007548101246356964, -0.1467408388853073, 0.054767657071352005, 0.003946784883737564, -0.19011707603931427, -0.0049020289443433285, 0.10642987489700317, 0.11020039021968842, 0.134551540017128, -0.1494969129562378, -0.09095986932516098, -0.015913598239421844, 0.1387517750263214, 0.06391526758670807, 0.026225930079817772, -0.17160144448280334, 0.01815095916390419, 0.08395946770906448, -0.05618796497583389, 0.07631193101406097, -0.05759016424417496, -0.021816641092300415, 0.057202067226171494, -0.013805035501718521, -0.04577576369047165, -0.0026008719578385353, -0.06540276110172272, 0.03972701355814934, -0.13310204446315765, -0.06294670701026917, -0.06804028898477554, 0.027351627126336098, 0.07057900726795197, 0.03842562809586525, 0.08650191128253937, 0.1709359586238861, -0.033655062317848206, 0.11419141292572021, -0.028698790818452835, 0.1802699863910675, 0.13034459948539734, 0.17172560095787048, 0.11416926980018616, 0.07844628393650055, -0.05696951970458031, 0.02468598075211048, 0.053485430777072906, 0.1092120110988617, -0.05781376361846924, -0.03792698681354523, 0.012010125443339348, -0.01175115816295147, -0.007394778076559305, -0.037185654044151306, -0.04088159650564194, 0.03779797628521919, 0.05006294324994087, -0.052530352026224136, 0.0340440608561039, -0.06875766813755035, -0.028891218826174736, -0.05776495486497879, -0.07855135202407837, -0.07644428312778473, -0.043426744639873505, -0.01596992090344429, 0.13104942440986633, -0.0170101597905159, -0.0032831900753080845, -0.05459381639957428, 0.06926801800727844, 0.040229104459285736, -0.0542667992413044, 0.004426795057952404, 0.13428106904029846, -0.004487818107008934, -0.21489116549491882, 0.09935801476240158, -0.06734822690486908, 0.05842454731464386, -0.002313510049134493, 0.0972069650888443, -0.0808742493391037, 0.15582776069641113, 0.06495725363492966, -0.047979842871427536, 3.8892365683687895e-33, -0.009781631641089916, 0.031116994097828865, -0.025664618238806725, 0.08060026913881302, 0.1770578920841217, -0.06666823476552963, -0.0013278629630804062, 0.023837845772504807, -0.10900471359491348, -0.106634721159935, -0.09613674879074097, 0.06829679012298584, 0.07106681168079376, 0.169448122382164, -0.02007589489221573, -0.08194473385810852, 0.03855850175023079, 0.016999641433358192, 0.024765806272625923, -0.12831293046474457, -0.12940946221351624, 0.050003524869680405, -0.06478884816169739, 0.08508269488811493, -0.018780438229441643, 0.13985492289066315, 0.019979070872068405, 0.06841324269771576, 0.11001315712928772, 0.03528229519724846, -0.17371848225593567, 0.09104922413825989, -0.05067285895347595, -0.1048922911286354, -0.0397057980298996, 0.021245036274194717, -0.10246928036212921, -0.1979108303785324, 0.03443826735019684, -0.0057480214163661, 0.0067473845556378365, 0.08998288214206696, -0.07527177035808563, -0.047929637134075165, 0.10555495321750641, -0.016618981957435608, -0.11544805020093918, 0.15900452435016632, 0.017727602273225784, -0.01062176562845707, 0.0878148227930069, -0.023964324966073036, 0.08990130573511124, -0.15124046802520752, -0.14434710144996643, 0.03017967939376831, -0.2903140187263489, -0.06512713432312012, 0.09196443855762482, 0.1948752999305725, -0.10485060513019562, -0.017352480441331863, -0.11338379234075546, 0.12854349613189697, -0.08461550623178482, 0.005537942983210087, 0.004045487381517887, -0.12280508875846863, -0.020504198968410492, 0.02691964991390705, -0.04529833793640137, 0.034496381878852844, 0.2689989507198334, -0.009194917976856232, 0.06985708326101303, -0.039005253463983536, 0.13234177231788635, 0.04625730589032173, 0.03907392919063568, 0.00843839906156063, 0.012688340619206429, 0.05035202205181122, -0.059358179569244385, 0.09335589408874512, -0.06309930980205536, -0.20256972312927246, -0.006036099046468735, 0.02298928052186966, -0.10527964681386948, -0.05142706260085106, 0.04479966312646866, -0.041101571172475815, -0.049023453146219254, 0.10662296414375305, 0.0463518388569355, -4.848122942507039e-33, 0.010189715772867203, -0.08153419941663742, -0.006360611878335476, -0.11021794378757477, 0.03526519611477852, 0.12930434942245483, 0.162031352519989, -0.021039707586169243, 0.10901171714067459, -0.18924348056316376, 0.14411607384681702, -0.030385546386241913, -0.041588082909584045, -0.04301111772656441, -0.15225106477737427, -0.03626684471964836, -0.010168461129069328, -0.10993731766939163, -0.13534963130950928, 0.04728960245847702, 0.0400041826069355, 0.19261489808559418, -0.11316108703613281, -0.013692738488316536, 0.006446855142712593, 0.044753558933734894, 0.05661986768245697, 0.08257488161325455, 0.10765352845191956, 0.059576332569122314, -0.04799367114901543, 0.04825463518500328, -0.2655976116657257, -0.03648698702454567, 0.03816036134958267, 0.13884273171424866, 0.034644559025764465, -0.13206882774829865, -0.04996323585510254, -0.08712375164031982, 0.2170848846435547, -0.025061296299099922, -0.1110917329788208, 0.01860859990119934, 0.1987687349319458, 0.09021267294883728, -0.0973929762840271, -0.04236990958452225, 0.0825343206524849, -0.09107977151870728, -0.006717809475958347, -0.0457456149160862, -0.045401573181152344, 0.019949693232774734, -0.03871571272611618, 0.0007336866110563278, 0.09061112999916077, -0.0770331397652626, 0.10879199206829071, 0.026334354653954506, -0.05440129339694977, 0.008136263117194176, 0.1049666702747345, -0.08122038841247559, 0.03389512374997139, 0.08758465945720673, 0.06362582743167877, -0.03283648192882538, 0.07226520776748657, -0.057143859565258026, 0.05891446769237518, -0.02214749902486801, -0.009324334561824799, -0.060022953897714615, -0.02845820225775242, 0.06692998111248016, -0.04057665914297104, -0.06218607723712921, -0.1874786615371704, 0.08656590431928635, 0.09073729813098907, -0.04639199376106262, 0.014995982870459557, 0.038245417177677155, 0.0901893824338913, 0.1242663785815239, 0.03121580183506012, 0.0728023573756218, -0.02666797861456871, 0.05916408449411392, -0.141384094953537, -0.18596911430358887, -0.13657495379447937, 0.13488119840621948, 0.046966202557086945, -1.0015551765718556e-07, 0.14874757826328278, 0.04905249923467636, 0.035930175334215164, -0.15403422713279724, -0.008896870538592339, 0.10065830498933792, -0.056831829249858856, 0.053401313722133636, -0.005895007401704788, 0.11119885742664337, 0.08238911628723145, 0.2266690731048584, -0.03669491782784462, 0.09913566708564758, -0.037375710904598236, 0.0753941535949707, -0.058321595191955566, -0.07401322573423386, -0.09543494135141373, -0.056620724499225616, -0.13760550320148468, 0.05928758159279823, -0.02832891419529915, 0.00015023443847894669, 0.08980835974216461, -0.15286056697368622, 0.007509048096835613, 0.0349615141749382, -0.027473732829093933, -0.059857435524463654, -0.06209211051464081, 0.03615410253405571, 0.04848894104361534, 0.029137469828128815, -0.06050015240907669, -0.1552743911743164, 0.10521538555622101, 0.07275789976119995, 0.030545830726623535, 0.11459040641784668, -0.0058246091939508915, 0.03383781015872955, 0.04712921008467674, -0.03534663841128349, -0.02537504956126213, -0.11259832978248596, -0.04158062860369682, -0.02197979763150215, 0.023394711315631866, 0.0054016392678022385, 0.03803368657827377, -0.08316859602928162, -0.027840815484523773, -0.14242587983608246, -0.07467649132013321, -0.009233644232153893, -0.0838828831911087, -0.12189610302448273, -0.006163083016872406, -0.10235585272312164, 0.01210619043558836, -0.030175618827342987, 0.10002351552248001, 0.06315714120864868], "changes": {"1wk": 11.475415694240846, "1mo": 14.754101106675396}}, {"text": "LIVE The latest news and updates on Trump's tariffs Is BellRing Brands (BRBR) Outperforming Other Medical Stocks This Year? Zacks Equity Research Tue, Nov 12, 2024, 5:40 PM 2 min read In This Article: BRBR +1.16% ALDX -1.34% For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has BellRing Brands (BRBR) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. BellRing Brands is one of 1024 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups. The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. BellRing Brands is currently sporting a Zacks Rank of #2 (Buy). Over the past three months, the Zacks Consensus Estimate for BRBR's full-year earnings has moved 1.1% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger. Based on the latest available data, BRBR has gained about 28.7% so far this year. Meanwhile, the Medical sector has returned an average of 4.7% on a year-to-date basis. This means that BellRing Brands is outperforming the sector as a whole this year. Another stock in the Medical sector, Aldeyra Therapeutics, Inc. (ALDX), has outperformed the sector so far this year. The stock's year-to-date return is 56.4%. For Aldeyra Therapeutics, Inc. the consensus EPS estimate for the current year has increased 5.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy). Looking more specifically, BellRing Brands belongs to the Medical - Products industry, which includes 87 individual stocks and currently sits at #85 in the Zacks Industry Rank. On average, this group has gained an average of 15% so far this year, meaning that BRBR is performing better in terms of year-to-date returns. On the other hand, Aldeyra Therapeutics, Inc. belongs to the Medical - Drugs industry. This 171-stock industry is currently ranked #68. The industry has moved +0.5% year to date. Investors with an interest in Medical stocks should continue to track BellRing Brands and Aldeyra Therapeutics, Inc. These stocks will be looking to continue their solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BellRing Brands Inc. (BRBR) : Free Stock Analysis Report Story Continues Aldeyra Therapeutics, Inc. (ALDX) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ALDX", "date": "2024-11-12T17:40:13", "sentiment": {"score": 0.8476283550262451, "confidence": 0.8687667846679688, "probabilities": {"positive": 0.8687667846679688, "negative": 0.021138429641723633, "neutral": 0.11009474843740463}}, "embedding": [-0.05532389134168625, -0.1584770381450653, -0.03401484340429306, 0.02568202093243599, -0.0770881325006485, 0.017630765214562416, 0.02270421013236046, 0.09430551528930664, 0.07487780600786209, -0.04860396683216095, -0.08293624967336655, 0.11654830724000931, 0.025998864322900772, -0.0551426038146019, -0.12221579253673553, 0.027747176587581635, 0.092889204621315, -0.09996622800827026, -0.1974477767944336, 0.08225098997354507, -0.10520663857460022, -0.07631822675466537, 0.1329883337020874, 0.0659293532371521, 0.047769851982593536, 0.06903014332056046, -0.061559047549963, -0.01728765293955803, -0.10693017393350601, -0.12882903218269348, -0.03183658793568611, 0.13177964091300964, 0.08326196670532227, -0.12970080971717834, -0.13520130515098572, -0.04002399370074272, -0.03443637117743492, 0.07192371040582657, 0.1623053252696991, 0.07006078958511353, 0.013635292649269104, -0.013306917622685432, -0.1478327512741089, 0.021984972059726715, -0.013633363880217075, -0.15196320414543152, 0.03885667026042938, 0.018485290929675102, 0.06425721198320389, 0.09983080625534058, -0.1372341364622116, -0.02419666200876236, 0.03149515017867088, 0.14365777373313904, -0.08305644989013672, 0.01536619197577238, -0.19332072138786316, -0.12083950638771057, 0.05027446150779724, 0.026018697768449783, 0.08790598809719086, 0.06684865057468414, 0.04509089142084122, 0.067628413438797, 0.05711336433887482, 0.019473865628242493, -0.09661570191383362, -0.0008265851065516472, -0.11858059465885162, -0.013090210035443306, 0.1339607834815979, -0.15192198753356934, -0.11766727268695831, 0.17669416964054108, 0.0008408681023865938, 0.12142930179834366, 0.17023035883903503, -0.013184696435928345, 0.10928375273942947, -0.006644121836870909, 0.0178599264472723, -0.021544944494962692, -0.0036972479429095984, -0.023778297007083893, 0.033974532037973404, -0.07630373537540436, 0.08174605667591095, 0.07988280057907104, 0.0002347547560930252, 0.03319614380598068, 0.10238911211490631, -0.053036488592624664, 0.0009387047030031681, -0.004000430461019278, 0.02544911950826645, 0.04458993673324585, -0.018432345241308212, 0.02440328523516655, -0.08012731373310089, 0.10891599208116531, 0.01832665503025055, 0.015678150579333305, -0.07875944674015045, -0.05654682219028473, -0.07202852517366409, -0.15765249729156494, 0.05568244308233261, 0.03899813070893288, 0.08800382912158966, -0.03245442360639572, -0.03708115965127945, 0.13304060697555542, -0.12469849735498428, -0.05874689295887947, -0.1641463041305542, 0.034550562500953674, -0.036092713475227356, -0.01055733673274517, 0.15967102348804474, 0.04881119355559349, 0.11649635434150696, 0.11178526282310486, 0.014294525608420372, -0.05494414269924164, 0.01035398431122303, 0.09692566841840744, -0.13913112878799438, 8.606268013530142e-33, 0.047894008457660675, 0.09692990779876709, 0.014543437398970127, 0.017123663797974586, -0.11918371915817261, -0.004179459065198898, -0.0755080059170723, -0.10426327586174011, -0.10308955609798431, -0.08789617568254471, -0.2318800687789917, 0.13778811693191528, -0.0416097417473793, -0.1041853129863739, 0.09855537861585617, -0.061674464493989944, -0.12210041284561157, -0.01570732705295086, -0.00023617781698703766, -0.06148765608668327, 0.04442063719034195, 0.06676667183637619, -0.0741068571805954, 0.08398360013961792, 0.0047957743518054485, -0.06595485657453537, 0.02524951845407486, -0.013264957815408707, -0.08321425318717957, 0.05886155366897583, 0.040889911353588104, 0.040010809898376465, 0.02910182997584343, -0.10155525803565979, -0.053087055683135986, -0.05320541933178902, -0.0271294005215168, -0.009591628797352314, 0.1346782147884369, 0.02796773985028267, -0.07508532702922821, 0.10673640668392181, -0.162035271525383, -0.01995960995554924, 0.07352825999259949, 0.07523126900196075, -0.1442834734916687, -0.060478806495666504, -0.0423126183450222, -0.05545180290937424, -0.09416522085666656, 0.04869505763053894, 0.09972409904003143, 0.025974957272410393, -0.03830479830503464, 0.07169746607542038, -0.070372074842453, -0.10634277760982513, 0.10189302265644073, 0.1331053078174591, 0.0021873582154512405, 0.13915538787841797, 0.08570178598165512, -0.04253426939249039, -0.12284889817237854, 0.09057900309562683, 0.005225985310971737, -0.022437643259763718, -0.16096574068069458, 0.07631433010101318, 0.017551572993397713, -0.039831213653087616, 0.14960996806621552, -0.08344782888889313, 0.12998004257678986, -0.05702519416809082, -0.04734022915363312, -0.0037842027377337217, -0.039619382470846176, 0.040794458240270615, 0.10755488276481628, 0.05375976115465164, 0.018428310751914978, 0.05191414803266525, -0.011255823075771332, -0.12889361381530762, -0.03669486939907074, -0.08947532624006271, -0.012773600406944752, 0.018055247142910957, -0.09187553822994232, -0.007949430495500565, -0.025026392191648483, 0.06520168483257294, 0.049810998141765594, -7.348297305634317e-33, -0.033559028059244156, -0.02586590126156807, 0.11064344644546509, -0.012745816260576248, -0.014182554557919502, -0.013667172752320766, 0.11029011011123657, 0.059814274311065674, -0.0011690401006489992, 0.006834108382463455, 0.10231292992830276, 0.11073103547096252, -0.15324324369430542, 0.012731235474348068, -0.00604783371090889, 0.09103289246559143, 0.09344719350337982, -0.14161396026611328, -0.057098086923360825, -0.13653342425823212, 0.05523785576224327, 0.1942853331565857, -0.1888929307460785, 0.147477924823761, -0.05942029505968094, 0.11426188051700592, 0.013141927309334278, 0.1683405339717865, 0.1635144054889679, -0.16817450523376465, -0.05417291820049286, 0.03421125188469887, -0.041428275406360626, 0.09490630030632019, -0.09859544038772583, 0.15133151412010193, 0.0840713381767273, -0.14142999053001404, -0.08472825586795807, -0.062331195920705795, 0.1835145652294159, -0.05026637017726898, -0.07077314704656601, -0.001712216529995203, 0.17162837088108063, -0.0204554982483387, 0.028424488380551338, -0.05077004432678223, 0.15276461839675903, 0.060977280139923096, 0.008092106319963932, 0.0973285511136055, -0.11526098847389221, 0.1882530152797699, -0.03633981570601463, -0.015180286951363087, -0.10447221249341965, -0.031213000416755676, -0.1964154690504074, -0.014276400208473206, 0.06659095734357834, 0.1748611032962799, 0.11608719825744629, -0.025827335193753242, -0.02419779635965824, -0.0008797601331025362, -0.003244405845180154, -0.04757916182279587, -0.00878795888274908, -0.07231059670448303, -0.007029776461422443, -0.04651714116334915, 0.03397494927048683, -0.13429808616638184, 0.05496641993522644, 0.230507493019104, -0.03470085188746452, -0.1311853528022766, -0.16486385464668274, 0.021482598036527634, 0.0015239929780364037, 0.024949299171566963, 0.07918460667133331, 0.02332388609647751, -0.0789719894528389, 0.13508331775665283, 0.05722438544034958, -0.042358122766017914, -0.1196623370051384, -0.02876455709338188, -0.07849763333797455, -0.2323743999004364, -0.1111874207854271, 0.021216342225670815, 0.006230357568711042, -9.99588820604913e-08, 0.01553407683968544, -0.11667709797620773, -0.005332638509571552, -0.03916417807340622, 0.0281287282705307, -0.011504627764225006, -0.015163304284214973, 0.029484959319233894, 0.09790030121803284, 0.11236977577209473, 0.1383514702320099, 0.05803264304995537, -0.26786738634109497, 0.029467064887285233, -0.0592079795897007, 0.08474909514188766, -0.13215115666389465, 0.03104107826948166, -0.018356095999479294, -0.17111793160438538, 0.02316822111606598, 0.1483881175518036, 0.19849547743797302, -0.04758226126432419, 0.03392497077584267, -0.051607146859169006, -0.10050877928733826, -0.03886934369802475, 0.026180485263466835, 0.10084639489650726, 0.04412003234028816, -0.008039440959692001, 0.08879885077476501, -0.006520859431475401, 0.04941767454147339, -0.1369655728340149, 0.015641827136278152, 0.06778144836425781, 0.03973574936389923, 0.0971994400024414, 0.08162739127874374, -0.057085804641246796, -0.01686931401491165, 0.07240404188632965, 0.016873039305210114, -0.11791126430034637, -0.028197437524795532, 0.0991518497467041, 0.17285911738872528, -0.1700129210948944, 0.15519288182258606, -0.1089697778224945, -0.009485957212746143, -0.026940805837512016, -0.09769336134195328, 0.10752014815807343, -0.10235844552516937, -0.09099994599819183, -0.1327810287475586, -0.027975980192422867, 0.00893098209053278, -0.2793295383453369, 0.13474203646183014, 0.18780076503753662], "changes": {"1wk": 3.8906401330611304, "1mo": 5.36277830291704}}, {"text": "LIVE The latest news and updates on Trump's tariffs Top US Penny Stocks To Watch In November 2024 editorial-team@simplywallst.com (Simply Wall St) Wed, Nov 20, 2024, 4:06 PM 4 min read In This Article: HYLN -5.53% ALDX -1.34% ADV -0.76% ADVWW -3.75% As the U.S. stock market shows signs of a modest recovery, with major indices inching higher ahead of key earnings reports, investors are keenly observing smaller sectors for potential opportunities. Penny stocks, despite their somewhat outdated moniker, continue to attract attention as they often represent emerging companies that could offer growth at lower entry points. This article explores three penny stocks that stand out for their financial resilience and potential to provide compelling investment opportunities amidst current market dynamics. Top 10 Penny Stocks In The United States Name Share Price Market Cap Financial Health Rating BAB (OTCPK:BABB) $0.827 $6.01M \u2605\u2605\u2605\u2605\u2605\u2605 QuantaSing Group (NasdaqGM:QSG) $3.08 $144.65M \u2605\u2605\u2605\u2605\u2605\u2605 Golden Growers Cooperative (OTCPK:GGRO.U) $4.50 $69.71M \u2605\u2605\u2605\u2605\u2605\u2605 PHX Minerals (NYSE:PHX) $3.56 $133.43M \u2605\u2605\u2605\u2605\u2605\u2606 So-Young International (NasdaqGM:SY) $1.25 $90.8M \u2605\u2605\u2605\u2605\u2606\u2606 ZTEST Electronics (OTCPK:ZTST.F) $0.27 $9.77M \u2605\u2605\u2605\u2605\u2605\u2605 Puma Biotechnology (NasdaqGS:PBYI) $2.74 $134.5M \u2605\u2605\u2605\u2605\u2605\u2605 Better Choice (NYSEAM:BTTR) $1.63 $2.97M \u2605\u2605\u2605\u2605\u2605\u2605 Zynerba Pharmaceuticals (NasdaqCM:ZYNE) $1.30 $65.6M \u2605\u2605\u2605\u2605\u2605\u2606 CBAK Energy Technology (NasdaqCM:CBAT) $0.8799 $79.14M \u2605\u2605\u2605\u2605\u2605\u2606 Click here to see the full list of 738 stocks from our US Penny Stocks screener. Let's uncover some gems from our specialized screener. Aldeyra Therapeutics Simply Wall St Financial Health Rating: \u2605\u2605\u2605\u2605\u2605\u2605 Overview: Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing and commercializing medicines for immune-mediated diseases, with a market cap of approximately $294.18 million. Operations: Aldeyra Therapeutics does not report any specific revenue segments. Market Cap: $294.18M Aldeyra Therapeutics is a pre-revenue biotech company with a market cap of approximately US$294.18 million, focusing on developing treatments for immune-mediated diseases. Despite being unprofitable, the company has reduced its debt-to-equity ratio from 28.3% to 18% over five years and maintains more cash than total debt. Recent earnings reports show increased losses; however, Aldeyra's short-term assets significantly exceed its liabilities, providing financial stability. The company's management team and board are experienced, supporting strategic initiatives like the resubmission of an NDA for reproxalap to treat dry eye disease, potentially enhancing future growth prospects. Click here to discover the nuances of Aldeyra Therapeutics with our detailed analytical financial health report. Assess Aldeyra Therapeutics' future earnings estimates with our detailed growth reports. NasdaqCM:ALDX Debt to Equity History and Analysis as at Nov 2024 Advantage Solutions Simply Wall St Financial Health Rating: \u2605\u2605\u2605\u2605\u2606\u2606 Story Continues Overview: Advantage Solutions Inc. offers business solutions to consumer goods manufacturers and retailers both in North America and internationally, with a market cap of approximately $1.08 billion. Operations: Advantage Solutions Inc. has not reported specific revenue segments, but it provides business solutions to consumer goods manufacturers and retailers across North America and internationally. Market Cap: $1.08B Advantage Solutions Inc., with a market cap of US$1.08 billion, faces challenges typical of penny stocks, including unprofitability and increasing losses over the past five years. Despite this, the company maintains a positive cash runway for over three years due to its sufficient short-term assets exceeding short-term liabilities by US$462.3 million. However, it struggles with high net debt to equity at 161% and long-term liabilities surpassing its short-term assets. Recent earnings reveal declining sales and increased net loss, but analysts expect significant earnings growth moving forward as Advantage continues its strategic transformation efforts. Unlock comprehensive insights into our analysis of Advantage Solutions stock in this financial health report. Evaluate Advantage Solutions' prospects by accessing our earnings growth report. NasdaqGS:ADV Debt to Equity History and Analysis as at Nov 2024 Hyliion Holdings Simply Wall St Financial Health Rating: \u2605\u2605\u2605\u2605\u2605\u2606 Overview: Hyliion Holdings Corp. develops sustainable electricity-producing technology focused on clean and efficient energy solutions, with a market cap of approximately $540.31 million. Operations: Hyliion Holdings Corp. has not reported any specific revenue segments. Market Cap: $540.31M Hyliion Holdings Corp., with a market cap of US$540.31 million, exemplifies the challenges and potential of penny stocks. The company is pre-revenue, focusing on innovative energy solutions like the KARNO generator, which recently demonstrated its versatile fuel capabilities. Despite being debt-free and having short-term assets of US$161.4 million exceeding liabilities, Hyliion faces financial hurdles with less than a year of cash runway if free cash flow continues to decline at historical rates. While unprofitable with a negative return on equity, its revenue is forecasted to grow significantly in the coming years as it targets sectors such as EV charging and data centers. Navigate through the intricacies of Hyliion Holdings with our comprehensive balance sheet health report here. Understand Hyliion Holdings' earnings outlook by examining our growth report. NYSEAM:HYLN Debt to Equity History and Analysis as at Nov 2024 Summing It All Up Jump into our full catalog of 738 US Penny Stocks here. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Searching for a Fresh Perspective? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Jump on the AI train with fast growing tech companies forging a new era of innovation. Find companies with promising cash flow potential yet trading below their fair value . This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqCM:ALDX NasdaqGS:ADV and NYSEAM:HYLN. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ALDX", "date": "2024-11-20T16:06:09", "sentiment": {"score": 0.20726881176233292, "confidence": 0.2238137125968933, "probabilities": {"positive": 0.2238137125968933, "negative": 0.016544900834560394, "neutral": 0.7596413493156433}}, "embedding": [-0.04973936825990677, -0.09926894307136536, -0.05627960339188576, -0.024651918560266495, 0.06437095999717712, 0.004563433583825827, 0.038054175674915314, 0.02660391479730606, -0.031671978533267975, -0.07782499492168427, -0.05725603923201561, -0.006063924171030521, 0.005311666987836361, 0.05334075540304184, -0.15579277276992798, 0.04795026779174805, 0.051772065460681915, 0.006274927407503128, -0.017667606472969055, 0.09248478710651398, -0.1128944605588913, -0.07183845341205597, 0.056525081396102905, 0.08561334013938904, -0.04473765939474106, 0.041899751871824265, -0.0009052148088812828, -0.029016917571425438, -0.27778369188308716, -0.18143543601036072, -0.04986023157835007, 0.04886816069483757, 0.0077575258910655975, -0.09419381618499756, -0.03363538533449173, -0.021246246993541718, 0.049439936876297, 0.06697438657283783, 0.09110216796398163, -0.03599405661225319, 0.03744612634181976, -0.04759988933801651, -0.07131398469209671, 0.03804286569356918, 0.0185401514172554, -0.1415582299232483, 0.02023916319012642, 0.0058181798085570335, 0.08627885580062866, 0.02141948975622654, -0.02128753624856472, 0.08848009258508682, 0.06503535062074661, 0.03802642971277237, -0.0954691618680954, 0.060293469578027725, -0.08016786724328995, 0.05236043035984039, 0.08952480554580688, -0.025754474103450775, 0.03224945813417435, 0.007689906284213066, 0.024103308096528053, -0.021717935800552368, 0.16902124881744385, -0.0006579374894499779, -0.13946713507175446, -0.04594965651631355, -0.06372244656085968, -0.15513843297958374, 0.0593964122235775, -0.10156150907278061, -0.08196943253278732, -0.01424437202513218, -0.07364098727703094, 0.06368392705917358, 0.16239392757415771, -0.0020506493747234344, 0.0768873542547226, -0.012874269858002663, -0.10658273845911026, -0.040513187646865845, 0.12649846076965332, -0.022522103041410446, -0.021289732307195663, 0.006513725966215134, 0.030558235943317413, -0.0056134965270757675, 0.04676935076713562, -0.10632908344268799, 0.07575702667236328, 0.007409917190670967, -0.13157904148101807, 0.055709853768348694, -0.0031472062692046165, -0.023608747869729996, -0.003793293610215187, 0.056956589221954346, -0.048964716494083405, 0.07727141678333282, 0.2521890103816986, -0.06781783699989319, -0.08147680759429932, -0.06434421986341476, -0.01641221158206463, -0.059341106563806534, 0.08606685698032379, -0.028067413717508316, 0.010018265806138515, 0.06385743618011475, 0.020959528163075447, 0.06714599579572678, -0.06528003513813019, -0.06013985723257065, -0.13639573752880096, 0.0010033119469881058, -0.14602933824062347, -0.13558411598205566, 0.1343403160572052, -0.04531040042638779, 0.07364369928836823, 0.051966696977615356, -0.10718557238578796, -0.008777457289397717, -0.08703689277172089, 0.03192870318889618, -0.07327667623758316, 1.5556520156772985e-32, -0.08179981261491776, 0.054009027779102325, -0.08390939980745316, -0.09723329544067383, -0.08108648657798767, 0.0523439422249794, 0.058046456426382065, -0.0773603692650795, -0.0936683788895607, -0.1129537895321846, -0.12717770040035248, 0.060064539313316345, -0.08291706442832947, 0.0006078910082578659, -0.13113108277320862, -0.1911386102437973, 0.052644629031419754, 0.009058305993676186, -0.002815245185047388, -0.11628842353820801, -0.029979512095451355, 0.15082335472106934, -0.17175795137882233, 0.06978227198123932, 0.01429117750376463, 0.034089744091033936, -0.06463173031806946, -0.14327973127365112, -0.00564125832170248, 0.05905488133430481, 0.048069193959236145, 0.09220246225595474, 0.02066056802868843, -0.062301989644765854, -0.11677582561969757, -0.05322229117155075, -0.11253425478935242, -0.037691839039325714, 0.0015146975638344884, -0.10427580773830414, -0.05430731922388077, 0.1725722849369049, -0.0828152522444725, 0.08850255608558655, -0.005094400607049465, 0.08662892132997513, -0.08285823464393616, 0.19407056272029877, 0.009566769003868103, -0.1608894169330597, -0.1600571870803833, -0.013245522044599056, -0.02542777918279171, 0.010593408718705177, -0.018102195113897324, 0.009195918217301369, -0.022596973925828934, -0.17170387506484985, 0.07106010615825653, 0.04511549323797226, 0.10191003978252411, 0.13161787390708923, -0.08923088014125824, 0.023144777864217758, -0.09056730568408966, 0.10586530715227127, 0.03684099391102791, 0.08859775960445404, -0.12344522029161453, 0.18974654376506805, -0.0613907091319561, -0.0312608927488327, 0.2957635521888733, 0.057268451899290085, 0.16269440948963165, -0.03629376366734505, 0.0386040136218071, 0.01947246864438057, 0.05093587934970856, -0.15441107749938965, 0.02695513144135475, -0.08181577920913696, 0.06671194732189178, 0.06294561922550201, -0.042181581258773804, -0.04013257101178169, -0.08378103375434875, 0.04759126156568527, 0.001664190785959363, -0.04219749569892883, 0.03485758602619171, -0.07366426289081573, 0.007065486162900925, 0.014487244188785553, -0.13020437955856323, -1.5794982410148733e-32, -0.03266213834285736, 0.011298220604658127, 0.003087415359914303, -0.039279572665691376, -0.0015235841274261475, -0.002025999128818512, 0.0011180380824953318, -0.05192888528108597, 0.004752360284328461, -0.04455488547682762, -0.03107825666666031, 0.007774580270051956, -0.01100294291973114, -0.020705729722976685, -0.036947399377822876, 0.15614357590675354, 0.022632312029600143, 0.00625387579202652, 0.03783167898654938, -0.09022051095962524, -0.12439241260290146, 0.14414456486701965, -0.15794774889945984, 0.06680586189031601, 0.01741880178451538, 0.026466943323612213, 0.0423588827252388, 0.0333917997777462, 0.06557959318161011, 0.06963320821523666, -0.0989581048488617, 0.0480174720287323, -0.08128668367862701, 0.11272631585597992, -0.05398397147655487, 0.126191183924675, 0.09026879817247391, -0.13928140699863434, -0.07495717704296112, 0.000735994428396225, 0.04430408403277397, -0.07884176820516586, 0.04276066645979881, 0.08067144453525543, 0.06716230511665344, 0.02201836183667183, -0.027590854093432426, 0.04618121311068535, 0.05489251762628555, 0.1620427519083023, 0.034023262560367584, 0.07452142238616943, 0.10589839518070221, 0.08047175407409668, -0.1559235155582428, 0.07770071923732758, -0.007077805697917938, 0.07012221217155457, -0.08674401044845581, -0.0830034613609314, -0.024572502821683884, 0.16593842208385468, 0.14357168972492218, 0.008427262306213379, -0.057958073914051056, 0.014271825551986694, -0.0635823979973793, 0.09724703431129456, -0.008454243652522564, -0.1077311635017395, 0.005953532177954912, 0.006123851984739304, 0.14244572818279266, -0.19300292432308197, 0.005087088793516159, 0.13779965043067932, -0.036360591650009155, 0.001374932937324047, 0.0048324838280677795, 0.14738976955413818, -0.012625972740352154, 0.07564139366149902, 0.11001269519329071, 0.0662689357995987, 0.08690530061721802, 0.0886772871017456, 0.009799505583941936, 0.09104993939399719, -0.07376512140035629, -0.013589859940111637, -0.015072398819029331, -0.08198687434196472, -0.04688060283660889, 0.009302960708737373, -0.08026538789272308, -1.0065752320542742e-07, 0.09745515882968903, -0.11505692452192307, -0.05530816689133644, -0.02413894608616829, 0.04299166798591614, 0.030402543023228645, 0.044005878269672394, 0.03377572447061539, 0.012014299631118774, 0.14249317348003387, 0.08318746089935303, 0.09460076689720154, -0.2076117992401123, -0.013984343968331814, -0.1020047515630722, -0.053801678121089935, -0.01958932727575302, 0.12264059484004974, -0.051743507385253906, 0.022521017119288445, 0.04192376881837845, 0.19216400384902954, 0.09565415978431702, -0.04507512226700783, 0.039424166083335876, 0.06336542963981628, -0.048949576914310455, 0.02207866683602333, 0.02995864301919937, 0.043593645095825195, -0.02171173132956028, 0.05102923512458801, 0.01782238483428955, -0.09276457130908966, 0.12496797740459442, 0.06491246819496155, -0.040277086198329926, 0.10787589848041534, 0.045625485479831696, 0.025212595239281654, -0.07400453090667725, -0.12023743987083435, 0.035571496933698654, 0.013793248683214188, 0.0752011239528656, -0.1493367850780487, -0.14270147681236267, 0.003547905944287777, 0.20814061164855957, -0.1805247813463211, -0.046498432755470276, -0.04355586692690849, -0.023115741088986397, -0.012384701520204544, 0.017339784651994705, 0.14554649591445923, -0.1604154407978058, -0.006762617267668247, -0.1236569732427597, -0.02456873469054699, 0.12034884095191956, -0.23396463692188263, 0.09213358908891678, 0.13464447855949402], "changes": {"1wk": 0.8403352926397583, "1mo": 2.100838231599396}}]